<?xml version="1.0" encoding="UTF-8"?>
<search_results count="94">
  <query>Daklinza</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <nct_id>NCT02159352</nct_id>
    <title>Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Darunavir</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">Lopinavir/Ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-093</other_id>
    </other_ids>
    <first_received>June 6, 2014</first_received>
    <start_date>June 2014</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>October 29, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>August 21, 2015</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) for Daclatasvir</outcome_measure>
      <outcome_measure>Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]) for Daclatasvir</outcome_measure>
      <outcome_measure>Time of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir</outcome_measure>
      <outcome_measure>Plasma Concentration Observed at 24 Hours Postdose (C24) of Daclatasvir</outcome_measure>
      <outcome_measure>Dose-normalized Maximum Observed Plasma Concentration (Cmax/D) and Dose-normalized Plasma Concentration Observed at 24 Hours Postdose (C24/D) of Daclatasvir</outcome_measure>
      <outcome_measure>Dose-normalized Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]/D) of Daclatasvir</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died</outcome_measure>
      <outcome_measure>Number of Participants With Abnormalities in Vital Sign Measurements</outcome_measure>
      <outcome_measure>Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings</outcome_measure>
      <outcome_measure>Number of Participants With Marked Abnormalities in Hematology Laboratory Test Results</outcome_measure>
      <outcome_measure>Number of Participants With Abnormalities in Urinalysis and Other Chemistry Testing Results</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02159352</url>
  </study>
  <study rank="2">
    <nct_id>NCT01830205</nct_id>
    <title>Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-063</other_id>
    </other_ids>
    <first_received>April 10, 2013</first_received>
    <start_date>September 2012</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>November 13, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>August 19, 2015</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Daclatasvir</outcome_measure>
      <outcome_measure>Unbound Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity Time (AUC(INF)u) of Daclatasvir</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of Daclatasvir</outcome_measure>
      <outcome_measure>Unbound Maximum Observed Plasma Concentrations of Daclatasvir</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From Time Zero to Last Measurable Concentration [AUC(0-T)] of Daclatasvir</outcome_measure>
      <outcome_measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Daclatasvir</outcome_measure>
      <outcome_measure>Plasma Half-life (T-half) of Daclatasvir</outcome_measure>
      <outcome_measure>Apparent Total Body Clearance (CLT/F) of Daclatasvir</outcome_measure>
      <outcome_measure>Unbound Apparent Clearance (CLU/F) of Daclatasvir</outcome_measure>
      <outcome_measure>Percent Urinary Recovery (%UR) of Daclatasvir</outcome_measure>
      <outcome_measure>Renal Clearance (CLR) of Daclatasvir</outcome_measure>
      <outcome_measure>Apparent Volume of Distribution (Vd/F) of Daclatasvir</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events and Who Died</outcome_measure>
      <outcome_measure>Number of Participants With Clinically Significant Laboratory Marked Abnormalities Reported as Adverse Events</outcome_measure>
      <outcome_measure>Number of Participants With Clinically Relevant Changes in Electrocardiogram (ECG) Reported as Adverse Events</outcome_measure>
      <outcome_measure>Number of Participants With Out-of-range Vital Signs Reported as Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
      <state>Minnesota</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01830205</url>
  </study>
  <study rank="3">
    <nct_id>NCT02262728</nct_id>
    <title>An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Research &amp; Development, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR105028</other_id>
      <other_id>TMC435HPC2010</other_id>
    </other_ids>
    <first_received>October 6, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>January 2020</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After end of Study Drug Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants with On-treatment Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants with SVR 4 Weeks After end of Study Drug Treatment (SVR4) and SVR 24 Weeks After end of Study Drug Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants with On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants with Viral Relapse</outcome_measure>
      <outcome_measure>Change From Baseline in HCV NS3/4A Sequence, NS5A and NS5B at Day 3, Week 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, and Year 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 After end of Treatment in Participants not Achieving SVR</outcome_measure>
      <outcome_measure>Percentage of Participants with Normalized Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels</outcome_measure>
      <outcome_measure>Time to Reach Maximum Plasma Concentration (Tmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-Time Curve from Time 0 to 24 hours After Dosing (AUC[0-24]) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Pre-dose (trough) Concentration (C0h) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Percentage of Participants with SVR12 who Maintain to have HCV RNA &lt;LLOQ Until the end of 5 years Follow up</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02262728</url>
  </study>
  <study rank="4">
    <nct_id>NCT02565888</nct_id>
    <title>A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Atazanavir</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">Cobicistat</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Radboud University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>UMCN-AKF 14.12</other_id>
    </other_ids>
    <first_received>September 30, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>September 30, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DATE-4</acronym>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>AUC</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02565888</url>
  </study>
  <study rank="5">
    <nct_id>NCT01938625</nct_id>
    <title>A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR102639</other_id>
      <other_id>TMC435HPC3016</other_id>
      <other_id>2013-002726-23</other_id>
    </other_ids>
    <first_received>September 5, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with a sustained virologic response (SVR)12 Weeks after the end of treatment</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of cyclosporine and tacrolimus</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[last]) of cyclosporine and tacrolimus</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of simprevir and daclatasvir</outcome_measure>
      <outcome_measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of simprevir and daclatasvir</outcome_measure>
      <outcome_measure>Predose (trough) concentration (C0h) of simprenavir and daclatasvir</outcome_measure>
      <outcome_measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of simprevir and daclatasvir</outcome_measure>
      <outcome_measure>Number of participants with dose adjustment of cyclosporine and tacrolimus during treatment with regimen simeprevir, daclatasvir and RBV</outcome_measure>
      <outcome_measure>Number of patients with a sustained virological response SVR4 after the end of treatment</outcome_measure>
      <outcome_measure>Number of participants with a sustained virologic response SVR24 after the end of treatment</outcome_measure>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
      <outcome_measure>Number of participants with Undetectable HCV RNA (less than 25 IU/mL undetectable) and HCV RNA less than 25 IU/mL detectable</outcome_measure>
      <outcome_measure>Number of participants with HCV RNA level less than 100 IU/mL</outcome_measure>
      <outcome_measure>Number of participants with on-treatment failure after treatment with regimen simeprevir, daclatasvir and RBV</outcome_measure>
      <outcome_measure>Number of participants with viral relapse after treatment with regimen simeprevir, daclatasvir and RBV</outcome_measure>
      <outcome_measure>Number of participants with HCV NS3/4A and NS5A sequences</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
      <country>Poland</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01938625</url>
  </study>
  <study rank="6">
    <nct_id>NCT02624063</nct_id>
    <title>Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir + Sofosbuvir</intervention>
      <intervention type="Drug">Simeprevir + Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Federal University of São Paulo</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>394</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TNT</other_id>
    </other_ids>
    <first_received>December 2, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>December 3, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Non-cirrhotic Subjects With Sustained Virologic Response at Follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Rapid Virologic Response at Week 4 (RVR)</outcome_measure>
      <outcome_measure>Percentage of Subjects With End of Treatment Response (EOTR)</outcome_measure>
      <outcome_measure>Treatment safety measured by the number of incidence of serious adverse event (SAEs), discontinuations due to adverse event (AEs), Grade 3/4 AEs and Grade 3/4 clinical laboratory abnormalities through the end of treatment.</outcome_measure>
      <outcome_measure>Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Non-cirrhotic Subjects With Relapse at Follow-up Week 12 (SVR12)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02624063</url>
  </study>
  <study rank="7">
    <nct_id>NCT02565862</nct_id>
    <title>A Drug-drug Interaction Study Between Daclatasvir and Metformin</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Diabetes Mellitus</condition>
      <condition>Insulin Resistance</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Metformin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Radboud University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>UMCN-AKF 14.11</other_id>
    </other_ids>
    <first_received>September 30, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>October 9, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DATE-3</acronym>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area Under the Curve (AUC)</outcome_measure>
      <outcome_measure>adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02565862</url>
  </study>
  <study rank="8">
    <nct_id>NCT01309932</nct_id>
    <title>Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Lambda (pegIFNλ)</intervention>
      <intervention type="Drug">BMS-790052 (NS5A Inhibitor)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">BMS-650032 (NS3 Protease Inhibitor)</intervention>
      <intervention type="Biological">Pegylated Interferon Alfa-2a (pegIFNα-2a)</intervention>
      <intervention type="Biological">Pegylated Interferon Lambda (pegIFNλ)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Biological">Pegylated Interferon Lambda (pegIFNλ)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">BMS-790052 (NS5A Inhibitor)</intervention>
      <intervention type="Drug">BMS-650032 (NS3 Protease Inhibitor)</intervention>
      <intervention type="Drug">Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)</intervention>
      <intervention type="Drug">Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)</intervention>
      <intervention type="Drug">Placebo for Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo for Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-008</other_id>
      <other_id>2010-022568-11</other_id>
    </other_ids>
    <first_received>March 4, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>D-LITE</acronym>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability (as measured by the frequency of serious adverse events (SAEs), dose reductions and discontinuations due to adverse events (AEs)</outcome_measure>
      <outcome_measure>Antiviral activity as determined by the proportion of Hepatitis C virus (HCV) genotype 1 subjects with 24-week sustained virologic response (SVR24)</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with Protocol definition of virologic response (PDR) for Part A and Part B</outcome_measure>
      <outcome_measure>Proportion of subjects with either a 2-log or greater decrease in Hepatitis C virus (HCV) Ribonucleic acid (RNA) levels from baseline or undetectable levels of HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with viral breakthrough, defined as confirmed &gt; 1 log10 increase in HCV RNA over nadir or confirmed HCV RNA ≥ Lower limit of quantitation (LLOQ) after confirmed undetectable HCV RNA while on treatment</outcome_measure>
      <outcome_measure>Proportion of subjects with undetectable HCV RNA at the end of treatment that develop detectable levels of HCV RNA in the post-treatment follow-up period</outcome_measure>
      <outcome_measure>Serum HCV Ribonucleic acid (RNA) levels over time</outcome_measure>
      <outcome_measure>Proportion of subjects with undetectable HCV RNA over time</outcome_measure>
      <outcome_measure>Time to viral clearance, defined as an absence of detectable HCV RNA</outcome_measure>
      <outcome_measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Maximum observed serum/plasma concentration (Cmax)</outcome_measure>
      <outcome_measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Time to maximum concentration (Tmax)</outcome_measure>
      <outcome_measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Minimal observed serum/plasma concentration (Cmin)</outcome_measure>
      <outcome_measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Area under the serum/plasma concentration-time curve during one dose interval AUC(TAU)</outcome_measure>
      <outcome_measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In all subjects, trough concentrations will be assessed (Ctrough)</outcome_measure>
      <outcome_measure>Proportion of subjects with 12-week sustained virologic response (SVR12), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with 4-week sustained virologic response (SVR4), defined as undetectable HCV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Japan</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01309932</url>
  </study>
  <study rank="9">
    <nct_id>NCT01628692</nct_id>
    <title>Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
      <collaborator>Janssen Research &amp; Development, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>230</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-062</other_id>
      <other_id>2012-000070-28</other_id>
    </other_ids>
    <first_received>June 25, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>October 29, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>August 13, 2015</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response Rate at Post-treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With End of Treatment Response (EOTR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12) by rs12979860 Single Nucleotide Polymorphisms in the IL-28B Gene Categories</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01628692</url>
  </study>
  <study rank="10">
    <nct_id>NCT02032888</nct_id>
    <title>A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>238</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-216</other_id>
    </other_ids>
    <first_received>January 9, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>August 21, 2015</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Treatment-naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV)/HIV-coinfected Treatment-naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV)/HIV-coinfected Treatment-experienced Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants of All Genotypes Coinfected With Hepatitis C Virus (HCV)/HIV Who Achieved Sustained Virologic Response Rate at Follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieve Hepatitis C Virus RNA Levels to be &lt;Lower Limit of Quantitation, Target Detected (TD)or Target Not Detected (TND) at Weeks: 1, 2, 4, 6, 8, and 12; at End of Treatment; and at Follow-up Weeks 4 and 24</outcome_measure>
      <outcome_measure>Percentage of Participants Coinfected With Hepatitis C Virus/HIV Who Achieved HCV RNA Levels&lt;Lower Limit of Quantitation (LLOQ), Target Not Detected (TND)</outcome_measure>
      <outcome_measure>Percentage of Participants With CC or Non-CC Genotype at the IL28B rs12979860 Single Nucleotide Polymorphisms Who Achieved Sustained Virologic Response at Follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Interruption or Discontinuation, Treatment-related AEs/SAEs and Grade 3 to 4 AEs/SAEs and Who Died During Treatment Period</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-related AEs/SAEs, Grade 3 to 4 AEs/SAEs, and Who Died During Follow-up Period</outcome_measure>
      <outcome_measure>Number of Participants With Treatment-emergent Grade 3-4 Abnormalities on Laboratory Test Results</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02032888</url>
  </study>
  <study rank="11">
    <nct_id>NCT02032901</nct_id>
    <title>Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>173</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-218</other_id>
    </other_ids>
    <first_received>January 9, 2014</first_received>
    <start_date>January 2014</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>September 29, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 12, 2015</firstreceived_results_date>
    <acronym>ALLY 3</acronym>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Treatment-Naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) Target Detected (TD) or Target Not Detected (TND)</outcome_measure>
      <outcome_measure>Percentage of Treatment-Experienced Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) Target Detected (TD) or Target Not Detected (TND)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response at Week 4 (RVR) Target Not Detected (TND)</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR) Target Not Detected (TND)</outcome_measure>
      <outcome_measure>Percentage of Participants With End of Treatment Response (EOTR) Target Not Detected (TND)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Hepatitis C Virus (HCV) RNA Levels Less Than the Lower Limit of Quantitation (LLOQ) - Target Not Detected (TND)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Hepatitis C Virus (HCV) RNA Levels Less Than the Lower Limit of Quantitation (LLOQ)- Target Detected (TD) or Target Not Detected (TND)</outcome_measure>
      <outcome_measure>Percentage of Participants With Or Without Cirrhosis at Baseline Who Achieved Sustained Virologic Response at Follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With CC or Non-CC Genotype at the IL28B rs12979860 Single Nucleotide Polymorphisms (SNPs) Who Achieved Sustained Virologic Response After 12 Weeks of Follow-up (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02032901</url>
  </study>
  <study rank="12">
    <nct_id>NCT02107365</nct_id>
    <title>Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Genotype 4 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon alpha-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC32 QUATTRO</other_id>
    </other_ids>
    <first_received>March 31, 2014</first_received>
    <start_date>November 2013</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>August 25, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12 Rate</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Treatment discontinuations</outcome_measure>
      <outcome_measure>Self-reported symptoms</outcome_measure>
      <outcome_measure>Patients' adherence</outcome_measure>
      <outcome_measure>SVR 24 rate</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
      <outcome_measure>Number of patients with virological failure under treatment</outcome_measure>
      <outcome_measure>HCV subtypic distribution</outcome_measure>
      <outcome_measure>Proportion of patients with resistance mutations to Asunaprevir and/or Daclatasvir in case of virological failure</outcome_measure>
      <outcome_measure>Cirrhosis evaluation</outcome_measure>
      <outcome_measure>Insulin resistance : HOMA-IR score</outcome_measure>
      <outcome_measure>Metabolic syndrome parameters</outcome_measure>
      <outcome_measure>Liver fibrosis</outcome_measure>
      <outcome_measure>Polymorphism of the gene of IL28B</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02107365</url>
  </study>
  <study rank="13">
    <nct_id>NCT01797848</nct_id>
    <title>Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo matching Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-047</other_id>
    </other_ids>
    <first_received>February 21, 2013</first_received>
    <start_date>June 2014</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>November 21, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>COMMAND-Asia</acronym>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Genotype 1 subjects with SVR24, defined as HCV RNA &lt; Limit of quantification (LOQ) at follow-up Week 24 for each cohort</outcome_measure>
      <outcome_measure>Proportion of Genotype (GT) 4 subjects with SVR24</outcome_measure>
      <outcome_measure>Proportion of GT 1 &amp; 4 subjects who achieve HCV RNA &lt; LOQ or undetectable</outcome_measure>
      <outcome_measure>Frequency of Serious Adverse Events (SAEs)/discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects with Sustained Virologic Response at follow up week 12 (SVR12) or SVR24 by rs12979860 Single nucleotide polymorphism (SNP) in the IL28B gene</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01797848</url>
  </study>
  <study rank="14">
    <nct_id>NCT00859053</nct_id>
    <title>Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatic Insufficiency</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-013</other_id>
    </other_ids>
    <first_received>March 6, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>September 9, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 10, 2015</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of BMS-790052</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Last Measurable Concentration [AUC(0-T)] of BMS-790052</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of BMS-790052</outcome_measure>
      <outcome_measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of BMS-790052</outcome_measure>
      <outcome_measure>Terminal Half-life (T-HALF) of BMS-790052</outcome_measure>
      <outcome_measure>Apparent Total Body Clearance (CLT/F) of BMS-790052</outcome_measure>
      <outcome_measure>Apparent Clearance of Free BMS-790052 (CLu/F)</outcome_measure>
      <outcome_measure>The Apparent Volume of Distribution at Steady State (Vss/F)</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Who Died</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00859053</url>
  </study>
  <study rank="15">
    <nct_id>NCT02323594</nct_id>
    <title>A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>88</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-111</other_id>
    </other_ids>
    <first_received>December 9, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>February 23, 2015</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum observed plasma concentration [Cmax]</outcome_measure>
      <outcome_measure>Area under the concentration-time curve [AUC] from time zero extrapolated to infinite time [AUC(INF)]</outcome_measure>
      <outcome_measure>AUC from time zero to the time of last quantifiable concentration [AUC(0-T)]</outcome_measure>
      <outcome_measure>Time of maximum observed plasma concentration [Tmax]</outcome_measure>
      <outcome_measure>Terminal plasma half life [T-HALF])</outcome_measure>
      <outcome_measure>Adverse Event reports</outcome_measure>
      <outcome_measure>Vital sign measurements</outcome_measure>
      <outcome_measure>ECGs</outcome_measure>
      <outcome_measure>Physical examinations</outcome_measure>
      <outcome_measure>Clinical laboratory tests</outcome_measure>
      <outcome_measure>The incidence of reported AEs will be tabulated and reviewed for potential significance and clinical importance.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02323594</url>
  </study>
  <study rank="16">
    <nct_id>NCT01616524</nct_id>
    <title>Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus (HCV)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated interferon lambda (pegIFNλ)</intervention>
      <intervention type="Biological">Pegylated interferon lambda (pegIFNλ)</intervention>
      <intervention type="Biological">Pegylated interferon alfa-2a (pegIFNα-2a)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo matching Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>880</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-017</other_id>
      <other_id>2011-004885-14</other_id>
    </other_ids>
    <first_received>June 7, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PRINCIPAL</acronym>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who achieve Sustained Virologic Response at post-treatment follow-up week 12 (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects with Rapid virologic response (RVR) [undetectable Hepatitis C virus (HCV) Ribonucleic acid (RNA)]</outcome_measure>
      <outcome_measure>Proportion of subjects with treatment emergent cytopenic abnormalities (anemia as defined by Hb &lt; 10 g/dL, neutropenia as defined by ANC &lt; 750 mm3 or thrombocytopenia as defined by platelets &lt; 50,000 mm3)</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment interferon-associated flu-like symptoms (as defined by pyrexia or chills or pain)</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)</outcome_measure>
      <outcome_measure>Proportion of subjects with Sustained Virologic Response at post-treatment follow-up week 24 (SVR24) by treatment group</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment Serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Proportion of subjects with dose reductions</outcome_measure>
      <outcome_measure>Proportion of subjects who discontinue due to Adverse events (AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12 in subjects with genotype-3 (GT-3) chronic HCV infection</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment constitutional symptoms (fatigue or asthenia)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Belgium</country>
      <country>Chile</country>
      <country>Finland</country>
      <country>France</country>
      <country>Greece</country>
      <country>Hong Kong</country>
      <country>Italy</country>
      <country>Japan</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Russian Federation</country>
      <country>Singapore</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Michigan</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01616524</url>
  </study>
  <study rank="17">
    <nct_id>NCT02551861</nct_id>
    <title>A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-377</other_id>
      <other_id>2015-003468-36</other_id>
    </other_ids>
    <first_received>September 15, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>June 2017</completion_date>
    <last_updated>November 18, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with sustained virologic response (SVR12) treated with Daclatasvir + Sofosbuvir (DCV+SOF)</outcome_measure>
      <outcome_measure>Safety measured by number of incidence of deaths, serious adverse events (SAE)s, discontinuation due to adverse events (AE)s, Grade 3/4 AEs and Grade 3/4 laboratory abnormalities observed from clinical laboratory testing</outcome_measure>
      <outcome_measure>Antiviral activity measured by the proportion of subjects who achieve HCV RNA &lt; lower limit of quantification (LLOQ) - at during and after treatment in each treatment arm</outcome_measure>
      <outcome_measure>Proportion of subjects with CC, CT or TT IL28B genotype who achieve SVR12 in each treatment arm</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02551861</url>
  </study>
  <study rank="18">
    <nct_id>NCT01428063</nct_id>
    <title>Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>228</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-026</other_id>
      <other_id>2011-000836-27</other_id>
    </other_ids>
    <first_received>September 1, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>February 6, 2015</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy based on the proportion of subjects with Sustained virologic response (SVR)12 [HCV Ribonucleic acid (RNA) &lt; LOQ at Follow-up week 12] for all subjects infected with genotype 1 who are prior non-responders to Peginterferon Alfa-2a/Ribavirin</outcome_measure>
      <outcome_measure>Efficacy as determined by the proportion of subjects with SVR12 in genotype 2, 3 &amp; 4 prior non-responders to pegIFNα-2a/RBV and treatment naive genotype 1b</outcome_measure>
      <outcome_measure>Safety measured by frequency of Serious Adverse Event(s) (SAE)s and discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve HCV RNA &lt; Limit of quantitation (LOQ) (detectable or undetectable) for each HCV genotype and treatment regimen</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve HCV RNA undetectable for each HCV genotype and treatment regimen</outcome_measure>
      <outcome_measure>Drug-resistant variants associated with virologic failure for each HCV genotype and treatment regimen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01428063</url>
  </study>
  <study rank="19">
    <nct_id>NCT01718158</nct_id>
    <title>Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon Lambda-1a</intervention>
      <intervention type="Biological">Peginterferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>444</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-021</other_id>
      <other_id>2011‐005409‐65</other_id>
    </other_ids>
    <first_received>October 29, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>STRUCTURE</acronym>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with Sustained Virologic Response at post-treatment follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR12 in treatment-naive subjects</outcome_measure>
      <outcome_measure>Proportion of subjects with rash related dermatologic events</outcome_measure>
      <outcome_measure>Proportion of subjects who develop treatment emergent cytopenic abnormalities</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment interferon (IFN) associated flu like/musculoskeletal symptoms</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR24 [Hepatitis C virus (HCV) Ribonucleic acid (RNA) &lt; Lower limit of quantitation (LLOQ)] at post-treatment follow-up Week 24</outcome_measure>
      <outcome_measure>Proportion of subjects with adverse events (AEs), Serious adverse events (SAEs), dose reductions, and discontinuations due to AEs through end of follow-up</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR12 with a 24-week treatment regimen</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve Extended rapid virologic response (eRVR) (HCV RNA &lt; LLOQ target not detected at Weeks 4 and 12 of treatment)</outcome_measure>
      <outcome_measure>Patient Health Questionnaire-9 (PHQ-9) score through end of follow-up</outcome_measure>
      <outcome_measure>Proportion of subjects with treatment emergent laboratory abnormalities by toxicity grade through End of treatment (EOT)</outcome_measure>
      <outcome_measure>Proportion of subjects with the following on-treatment interferon-associated neuropsychiatric symptoms through EOT</outcome_measure>
      <outcome_measure>Association of Single nucleotide polymorphism (SNPs) in Interleukin 28B (IL28B) (including rs12979860) or equilibrative nucleoside transporter 1 (ENT1) with clinical responses</outcome_measure>
      <outcome_measure>Resistant variants associated with virologic failure through end of follow-up</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Japan</country>
      <country>Korea, Republic of</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Georgia</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01718158</url>
  </study>
  <study rank="20">
    <nct_id>NCT00663208</nct_id>
    <title>A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>167</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-004</other_id>
    </other_ids>
    <first_received>April 18, 2008</first_received>
    <start_date>May 2008</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>September 16, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 14, 2015</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline at Day 7 in log10 Hepatitis C Virus (HCV) RNA of All Participants</outcome_measure>
      <outcome_measure>Change From Baseline at Day 7 in log10 Hepatitis C Virus (HCV) RNA Levels of Participants Without Baseline Drug Resistance</outcome_measure>
      <outcome_measure>Change From Baseline at 24 h Post Dose on Day 1 in log10 Hepatitis C Virus (HCV) RNA of Participants Without Baseline Drug Resistance</outcome_measure>
      <outcome_measure>Change From Baseline to Day 4 in log10 Hepatitis C Virus (HCV) RNA in Participants Without Baseline Drug Resistance</outcome_measure>
      <outcome_measure>Change From Baseline to Day 14 in Log10 Hepatitis C Virus (HCV) RNA in Participants Without Baseline Drug Resistance</outcome_measure>
      <outcome_measure>Time to Maximum Decline From Baseline in Hepatitis C Virus (HCV) RNA in Participants Without Baseline Drug Resistance</outcome_measure>
      <outcome_measure>Maximum Decline From Baseline in Log10 Hepatitis C Virus (HCV) RNA in Participants Without Baseline Drug Resistance</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Cmin) of Daclatasvir on Days 1 and 14</outcome_measure>
      <outcome_measure>Area Under the Concentration-time Curve (AUC) in 1 Dosing Interval of Daclatasvir at Days 1 and 14</outcome_measure>
      <outcome_measure>Plasma Half-life (T-half) of Daclatasvir at Day 14</outcome_measure>
      <outcome_measure>Apparent Total Body Clearance (CLT/F) of Daclatasvir on Day 14</outcome_measure>
      <outcome_measure>Average Observed Plasma Concentration (Css-av) at Steady State of Daclatasvir at Days 1 and 14</outcome_measure>
      <outcome_measure>Accumulation Index (AI) AUC(TAU), AI Cmax, and Degree of Fluctuation (DF) of Daclatasvir on Day 14</outcome_measure>
      <outcome_measure>Time of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir on Days 1 and 14</outcome_measure>
      <outcome_measure>Correlation Coefficients Between Measures of Decline in log10 Hepatitis C Virus (HCV) RNA and Daclatasvir PK Parameters Cmax, AUC(TAU), and Cmin on Day 14 in Participants Without Baseline Drug Resistance</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuation Due to Adverse Events (AEs), and Who Died</outcome_measure>
      <outcome_measure>Number of Participants With Marked Laboratory Abnormalities in Hematology</outcome_measure>
      <outcome_measure>Number of Participants With Marked Abnormalities in Liver and Kidney Function Laboratory Tests and Electrolytes</outcome_measure>
      <outcome_measure>Number of Participants With Marked Laboratory Abnormalities in Lipase and Glucose</outcome_measure>
      <outcome_measure>Number of Participants With Marked Laboratory Abnormalities in Urinalysis</outcome_measure>
      <outcome_measure>Number of Participants With Clinically Relevant Change From Baseline in Vital Signs</outcome_measure>
      <outcome_measure>Number of Participants Meeting Pre-Specified Criteria in Electrocardiogram Parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00663208</url>
  </study>
  <study rank="21">
    <nct_id>NCT02596880</nct_id>
    <title>Sofosbuvir, Daclatasvir, Ribavirin for HCV Cirrhotics</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tehran University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>94-02-159-30278</other_id>
    </other_ids>
    <first_received>November 3, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>November 9, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SD100</acronym>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The sustained viral response rate</outcome_measure>
      <outcome_measure>Adverse drug events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02596880</url>
  </study>
  <study rank="22">
    <nct_id>NCT01448044</nct_id>
    <title>Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052 (NS5A Replication Complex Inhibitor)</intervention>
      <intervention type="Drug">Placebo matching BMS-790052</intervention>
      <intervention type="Drug">Pegylated-interferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>152</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-042</other_id>
      <other_id>2011-002793-23</other_id>
    </other_ids>
    <first_received>October 5, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>September 11, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 7, 2015</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With 12 Week Sustained Virologic Response (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieve HCV Ribonucleic Acid (RNA) &lt; Limit of Quantification (LLOQ)</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable Hepatitis C Virus (HCV) RNA Levels</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) or Sustained Virologic Response at Follow-up Week 24 (SVR24) by rs12979860 Single Nucleotide Polymorphism (SNP) in the IL28B Gene</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Massachusetts</state>
      <state>Rhode Island</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01448044</url>
  </study>
  <study rank="23">
    <nct_id>NCT01455090</nct_id>
    <title>Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-791325</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>320</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-014</other_id>
      <other_id>2011-002788-11</other_id>
    </other_ids>
    <first_received>October 18, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR) at 12 weeks post-treatment (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV ribonucleic acid (RNA) &lt; limit of quantification (LOQ) (detectable and undetectable)</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV ribonucleic acid (RNA) undetectable</outcome_measure>
      <outcome_measure>Proportion of subjects who experience viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of subjects who experience viral relapse defined as confirmed quantifiable HCV RNA ≥ 25 IU/mL (&gt;LOQ) in a subject with HCV RNA &lt; LOQ or undetectable at End of treatment (EOT)</outcome_measure>
      <outcome_measure>Maximum observed plasma concentration (Cmax) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</outcome_measure>
      <outcome_measure>Observed plasma concentration at 12 hours (C12) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</outcome_measure>
      <outcome_measure>Observed plasma concentration at 24 hours (C24) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</outcome_measure>
      <outcome_measure>Trough observed plasma concentration (Ctrough) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</outcome_measure>
      <outcome_measure>Time of maximum observed plasma concentration (Tmax) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</outcome_measure>
      <outcome_measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</outcome_measure>
      <outcome_measure>HCV genomic substitutions associated with exposure of BMS-650032, BMS-790052, and BMS-791325</outcome_measure>
      <outcome_measure>Frequency of deaths, serious adverse events (SAEs), discontinuations due to adverse events (AEs), severity Grade 3/4 AEs, and severity Grade 3/4 laboratory abnormalities</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>Oklahoma</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01455090</url>
  </study>
  <study rank="24">
    <nct_id>NCT01629732</nct_id>
    <title>Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">BMS-986094</intervention>
      <intervention type="Drug">BMS-986094</intervention>
      <intervention type="Drug">BMS-986094</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo for BMS-986094</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI472-007</other_id>
      <other_id>2012-002519-24</other_id>
    </other_ids>
    <first_received>June 26, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>May 8, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with SVR4 defined as HCV RNA &lt; LOQ (25 IU/mL; detectable or undetectable) at 4 weeks post treatment to be evaluated in GT1 (naive and NR) subjects randomized to the 12-week treatment arm (arms 1a, 2a, 3a, 4a)</outcome_measure>
      <outcome_measure>Proportion of treated subjects with SVR4 in genotype (GT) 1 naive and non-responder (NR) subjects randomized to the 24-week treatment arms (arms 1b, 2b, 3b, 4b)</outcome_measure>
      <outcome_measure>Proportion of treated subjects with SVR4 in genotype 1 protease inhibitor (PI)failures, genotype 4 naive, and genotype 2/3 NR/relapse subjects (arms 5, 6, 7)</outcome_measure>
      <outcome_measure>Proportion of treated subjects in each study population (GT1 naive, GT1 NR, or GT1 PI-failure, GT4 naive, GT2/3 NR/relapse), for each regimen and duration, who achieve HCV RNA &lt; LOQ at post-treatment</outcome_measure>
      <outcome_measure>Proportion of treated subjects in each study population, by regimen, who achieve HCV RNA &lt; LOQ (detectable/undetectable)</outcome_measure>
      <outcome_measure>Proportion of subjects in each study population, be regimen, who achieve HCV RNA undetectable</outcome_measure>
      <outcome_measure>Safety and tolerability of BMS-986094 and DCV ± RBV as measured by the frequency of deaths, serious adverse events (SAEs), discontinuations due to Adverse Events (AEs), and severity Grade 3/4 laboratory abnormalities</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01629732</url>
  </study>
  <study rank="25">
    <nct_id>NCT02123654</nct_id>
    <title>UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">DCV 3DAA</intervention>
      <intervention type="Other">Placebo for DCV 3DAA</intervention>
      <intervention type="Other">Placebo for Daclatasvir</intervention>
      <intervention type="Other">Placebo for Asunaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>297</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-117</other_id>
    </other_ids>
    <first_received>April 10, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>September 16, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects who achieve SVR12 in treatment-naive non-cirrhotic subjects treated with DCV/ASV/BMS-791325, defined as HCV RNA &lt; LOQ target detected or target not detected (LOQ TD/TND) at post-treatment follow-up Week 12</outcome_measure>
      <outcome_measure>The proportion of treatment-naive subjects who achieve SVR12 with DCV/ASV/BMS-791325 or DCV/ASV</outcome_measure>
      <outcome_measure>The proportion of Interferon (IFN) experienced subjects who achieve SVR12 with DCV/ASV/BMS-791325</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve HCV RNA &lt; LOQ TD/TND at each of the following Weeks: 1, 2, 4, 6, 8, 12, 16, 20 and 24; EOT; post-treatment Weeks 4 (SVR4), 8 (SVR8) and 24 (SVR24)</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve HCV RNA &lt; LOQ TND at each of the following Weeks: 1, 2, 4, 6, 8, 12, 16, 20 and 24; EOT; post-treatment Weeks 4, 8, 12 and 24</outcome_measure>
      <outcome_measure>On-treatment safety as measured by the frequency of Serious Adverse Event (SAEs), discontinuations due to Adverse Event (AEs), and selected Grade 3 - 4 laboratory abnormalities</outcome_measure>
      <outcome_measure>The proportion of subjects with anemia defined as Hb &lt; 10 g/dL on-treatment who had Hb ≥ 10 g/dL at baseline</outcome_measure>
      <outcome_measure>The proportion of subjects in each cohort who achieve SVR12 associated with HCV genotype subtype 1a vs 1b</outcome_measure>
      <outcome_measure>The proportion of subjects in each cohort who achieve SVR12 associated with IL28B Single Nucleotide Polymorphisms (SNP) status</outcome_measure>
      <outcome_measure>The proportion of cirrhotic and non-cirrhotic subjects who achieve SVR12</outcome_measure>
      <outcome_measure>On-treatment safety of non-cirrhotic vs cirrhotic subjects, as measured by the frequency of SAEs, discontinuations due to AEs, and selected Grade 3 - 4 laboratory abnormalities on DAIDS criteria</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02123654</url>
  </study>
  <study rank="26">
    <nct_id>NCT01425970</nct_id>
    <title>Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">Placebo matching with INX-08189</intervention>
      <intervention type="Biological">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI472-003</other_id>
      <other_id>INH-189-003</other_id>
    </other_ids>
    <first_received>August 25, 2011</first_received>
    <start_date>May 2012</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>October 12, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part A: Change in Hepatitis C Viral Load Measurements at protocol specific timepoints</outcome_measure>
      <outcome_measure>Part B: proportion of subjects with SVR defined as HCV RNA ≤ LOQ (Limit of Quantitation)</outcome_measure>
      <outcome_measure>Part B: proportion of subjects with SVR defined as HCV RNA ≤ LOQ</outcome_measure>
      <outcome_measure>Safety assessments is measured by Physical Exams, vital signs, laboratory assessments, ECGs, pregnancy test, viral resistance testing, adverse event assessment</outcome_measure>
      <outcome_measure>Proportion of subjects with RVR (Rapid Virologic Response), undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with Complete EVR (Early Virologic Response), undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with Extended RVR</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Missouri</state>
      <state>Oklahoma</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01425970</url>
  </study>
  <study rank="27">
    <nct_id>NCT02268864</nct_id>
    <title>A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>106</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR105490</other_id>
      <other_id>2014-003413-28</other_id>
      <other_id>TMC435HPC2019</other_id>
    </other_ids>
    <first_received>October 15, 2014</first_received>
    <start_date>January 2015</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>COMMIT</acronym>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After end of Study Drug Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants with SVR 4 Weeks After end of Study Drug Treatment (SVR4) and SVR 24 Weeks After end of Study Drug Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants with On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants with viral breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02268864</url>
  </study>
  <study rank="28">
    <nct_id>NCT02349048</nct_id>
    <title>Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir 150 mg</intervention>
      <intervention type="Drug">Daclatasvir 60 mg</intervention>
      <intervention type="Drug">Sofosbuvir 400 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Research &amp; Development, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR105963</other_id>
      <other_id>TMC435HPC2013</other_id>
    </other_ids>
    <first_received>January 22, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>December 11, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ACCORDION-1</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 12 Weeks After end of Study Drug Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 Weeks (SVR4) and 24 Weeks (SVR24) After end of Study Drug Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Change from Baseline in HCV Nonstructural Protein 3/4A (NS3/4A), NS5A and NS5B Sequence in Participants not Achieving SVR</outcome_measure>
      <outcome_measure>Percentage of Participants With or Without an NS3 Q80K Polymorphism at Baseline Achieving SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>North Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02349048</url>
  </study>
  <study rank="29">
    <nct_id>NCT02032875</nct_id>
    <title>Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>116</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-215</other_id>
    </other_ids>
    <first_received>January 9, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>August 18, 2015</firstreceived_results_date>
    <acronym>ALLY 1</acronym>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Genotype-1 Infected Cirrhotic Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Genotype-1 Infected Post-liver Transplanted Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Sustained Virologic Response at Post-treatment Week 12 (SVR12) for All Genotypes and Genotypes 2, 3, 4, 6</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieve Hepatitis C Virus RNA Levels to be &lt; Lower Limit of Quantitation Target Detected or Target Not Detected at Each of the Following Weeks: 1, 2, 4, 6, 8, 12, End of Treatment; Follow Up Weeks 4, 8 and 12</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieve Hepatitis C Virus RNA Levels to be &lt; Lower Limit of Quantitation Target Not Detected at Each of the Following Weeks: 1, 2, 4, 6, 8, 12, End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With CC or Non-CC Genotype Who Achieved Sustained Virologic Response at 12 Weeks After the Last Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), AEs Leading to Interruption, Treatment-related AEs/SAEs, Grade 3 to 4 AEs/SAEs, and Who Died During Treatment Period</outcome_measure>
      <outcome_measure>Number of Participants With Treatment Emergent Grade 3-4 Laboratory Abnormalities</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
      <state>Michigan</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02032875</url>
  </study>
  <study rank="30">
    <nct_id>NCT01718145</nct_id>
    <title>A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">pegIFNα-2b</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>258</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-031</other_id>
    </other_ids>
    <first_received>October 29, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with SVR12, defined as HCV RNA target detected or target not detected below LLOQ in the naive cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with hemoglobin &lt; 10g/dL</outcome_measure>
      <outcome_measure>Proportion of subjects with rash-related dermatologic events</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target detected or target not detected below LLOQ in the naive cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target not detected in the naive cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12, defined as HCV RNA target detected or target not detected below LLOQ in the relapser cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target detected or target not detected below LLOQ in the relapser cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target not detected in the relapser cohort</outcome_measure>
      <outcome_measure>On treatment safety, as measured by the frequency of Severe adverse events (SAEs), discontinuation and dose modification/interruption due to Adverse events (AEs), Grade 3-4 abnormalities observed from clinical laboratory tests for each treatment group</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01718145</url>
  </study>
  <study rank="31">
    <nct_id>NCT02397395</nct_id>
    <title>An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Renal Impairment</condition>
      <condition>End-stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir (SMV) 150 mg</intervention>
      <intervention type="Drug">Daclatasvir (DCV) 60 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR106396</other_id>
      <other_id>TMC435HPC2018</other_id>
      <other_id>2014-004250-34</other_id>
    </other_ids>
    <first_received>March 19, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>July 15, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 After End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 4 After End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 24 After End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With on-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Change From Baseline in Hepatitis C Virus (HCV) Nonstructural Protein 3/4A (NS3/4A) and Nonstructural Protein 5A (NS5A) Sequence in Participants not Achieving SVR</outcome_measure>
      <outcome_measure>Change From Baseline in HCV Symptom and Impact Questionnaire version 4 (HCV-SIQv4) Overall Body Symptom score</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02397395</url>
  </study>
  <study rank="32">
    <nct_id>NCT02304159</nct_id>
    <title>Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tarek I. Hassanein, M.D., FACP, FAG, AGAF</lead_sponsor>
      <collaborator>Southern California Research Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444284</other_id>
    </other_ids>
    <first_received>November 17, 2014</first_received>
    <start_date>January 2015</start_date>
    <completion_date>November 2017</completion_date>
    <last_updated>November 21, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
      <outcome_measure>Number of participants with abnormal safety laboratory tests (ALT and/or Total Bilirubin) that required discontinuing study drugs</outcome_measure>
      <outcome_measure>Number of participants with undetectable HCV virus 12 weeks after stopping study drugs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02304159</url>
  </study>
  <study rank="33">
    <nct_id>NCT02104843</nct_id>
    <title>Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir, Asunaprevir and BMS-791325 FDC</intervention>
      <intervention type="Drug">BMS-791325</intervention>
      <intervention type="Drug">Rosuvastatin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-115</other_id>
    </other_ids>
    <first_received>April 2, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>July 17, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum observed concentration (Cmax) of Rosuvastatin</outcome_measure>
      <outcome_measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) of Rosuvastatin</outcome_measure>
      <outcome_measure>Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Rosuvastatin</outcome_measure>
      <outcome_measure>Time of maximum observed concentration (Tmax) of Rosuvastatin</outcome_measure>
      <outcome_measure>Half life (T-HALF) of Rosuvastatin</outcome_measure>
      <outcome_measure>Apparent total body clearance (CLT/F) of Rosuvastatin</outcome_measure>
      <outcome_measure>Maximum observed concentration (Cmax) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712</outcome_measure>
      <outcome_measure>Trough observed plasma concentration (predose) (Ctrough) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712</outcome_measure>
      <outcome_measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712</outcome_measure>
      <outcome_measure>Time of maximum observed concentration (Tmax) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712</outcome_measure>
      <outcome_measure>Observed plasma concentration at 12 hours after dosing in a pharmacokinetic (PK) profile (C12) of Daclatasvir, Asunaprevir and BMS-791325 and BMS-794712</outcome_measure>
      <outcome_measure>Safety measured by incidence of Adverse events (AEs), Serious adverse events (SAEs) and AEs leading to discontinuation</outcome_measure>
      <outcome_measure>Safety measured by results of vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02104843</url>
  </study>
  <study rank="34">
    <nct_id>NCT00874770</nct_id>
    <title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alpha-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-014</other_id>
      <other_id>EUDRACT# 2009-010149-29</other_id>
    </other_ids>
    <first_received>April 2, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 6, 2015</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR) at Weeks 4 and 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR) at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With a Complete Early Virologic Response (cEVR) at Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00874770</url>
  </study>
  <study rank="35">
    <nct_id>NCT02309450</nct_id>
    <title>Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Genotype 4 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">.Asunaprevir, Daclatasvir and BMS - 791325</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRSHC33QUATTROTURBO</other_id>
      <other_id>2014-002724-27</other_id>
    </other_ids>
    <first_received>October 31, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>December 3, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>QUATTROTURBO</acronym>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV sustained virological response rate</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Treatment interruptions</outcome_measure>
      <outcome_measure>Causes of treatment discontinuation</outcome_measure>
      <outcome_measure>Self-reported symptoms</outcome_measure>
      <outcome_measure>Patients adherence rate</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
      <outcome_measure>Evaluation of the relationship between HCV subtypic distribution at baseline (by sequencing of the HCV NS5B domain) and the virological kinetics and response</outcome_measure>
      <outcome_measure>Proportion of patients with resistance mutations to Asunaprevir and/or Daclatasvir and/or BMS in case of virological failure</outcome_measure>
      <outcome_measure>Child-Pugh score (composite measure)</outcome_measure>
      <outcome_measure>Insulin resistance measured using the HOMA-IR score</outcome_measure>
      <outcome_measure>Parameters that define metabolic syndrome</outcome_measure>
      <outcome_measure>Evolution of liver fibrosis</outcome_measure>
      <outcome_measure>MELD score (composite measure)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02309450</url>
  </study>
  <study rank="36">
    <nct_id>NCT01842451</nct_id>
    <title>A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>CHC</condition>
      <condition>HCV</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VX-135</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>23</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX13-135-105</other_id>
    </other_ids>
    <first_received>April 24, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>October 23, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The safety and tolerability as assessed by adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), echocardiograms, and laboratory assessments</outcome_measure>
      <outcome_measure>The proportion of subjects who have a sustained virologic response (SVR; i.e., HCV RNA concentration below the lower limit of quantitation [&lt;LLOQ; &lt;25 IU/mL]) at 4 weeks after the last planned dose of treatment (SVR4)</outcome_measure>
      <outcome_measure>The proportion of subjects who have an SVR at 12 weeks after the last planned dose of treatment (SVR12)</outcome_measure>
      <outcome_measure>The proportion of subjects who have an SVR at 44 weeks after the last planned dose of treatment (SVR24)</outcome_measure>
      <outcome_measure>The proportion of subjects who have virologic relapse</outcome_measure>
      <outcome_measure>The proportion of subjects who have virologic breakthrough</outcome_measure>
      <outcome_measure>The amino acid sequence of the nonstructural NS5A and NS5B proteins in subjects who have treatment failure</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve SVR12 by HCV genotype 1 subtype (1a versus non-1a)</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve SVR12 by IL-28B genotype (CC versus non-CC)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01842451</url>
  </study>
  <study rank="37">
    <nct_id>NCT02496078</nct_id>
    <title>A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Asunaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-114</other_id>
    </other_ids>
    <first_received>July 9, 2015</first_received>
    <start_date>August 2015</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects randomized to Active Dual therapy with Sustained Virologic Response (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects with anemia on active Dual therapy</outcome_measure>
      <outcome_measure>Proportion of subjects with neutropenia on active Dual therapy</outcome_measure>
      <outcome_measure>Proportion of subjects with thrombocytopenia on active Dual therapy</outcome_measure>
      <outcome_measure>On treatment safety, as measured by frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</outcome_measure>
      <outcome_measure>Differences in rates of selected Grade 3-4 laboratory abnormalities for hematology between treatments (DCV + Asunaprevir (ASV) vs PBO)</outcome_measure>
      <outcome_measure>Differences in rates of selected Grade 3-4 laboratory abnormalities for liver function between treatments (DCV + Asunaprevir (ASV) vs PBO)</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12 by the rs12979860 single nucleotide polymorphism (SNP) in the interleukin (IL) -28B gene for each cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with hepatitis C virus (HCV) RNA &lt; LLOQ-TD/TND in each arm at various intervals after the initiation of active Dual therapy</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve HCV RNA &lt; LLOQ-TND at each arm at various intervals after the initiation of active Dual therapy</outcome_measure>
      <outcome_measure>Proportion of treated subjects with SVR12 for subjects randomized to placebo</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Korea, Republic of</country>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02496078</url>
  </study>
  <study rank="38">
    <nct_id>NCT02319031</nct_id>
    <title>Safety and Efficacy Study of Daclatasvir 60mg, Sofosbuvir 400mg, and Ribavirin (Dosed Based Upon Weight) in Subjects With Chronic Genotype 3 Hepatitis C Infection With or Without Prior Treatment Experience and Compensated Advanced Cirrhosis for 12 or 16 Weeks</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-326</other_id>
    </other_ids>
    <first_received>December 12, 2014</first_received>
    <start_date>February 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with sustained virologic response a follow up Weeks 12 (SVR12), defined as HCV RNA &lt; lower limit of quantification (LLOQ) target detected (TD) or target not detected (TND)</outcome_measure>
      <outcome_measure>On treatment safety, as measured by frequency of Serious Adverse Event (SAE)s, discontinuation due to Adverse Event (AE)s, Grade 3/4 AEs, and Grade 3/4 laboratory abnormalities</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve HCV RNA &lt; LLOQ-TD/TND</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02319031</url>
  </study>
  <study rank="39">
    <nct_id>NCT01492504</nct_id>
    <title>Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1850</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-046</other_id>
      <other_id>2011-005287-21</other_id>
    </other_ids>
    <first_received>November 30, 2011</first_received>
    <start_date>February 2012</start_date>
    <completion_date>February 2021</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2021</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Durability of Sustained viral response [SVR] (time to loss of virologic response)</outcome_measure>
      <outcome_measure>Frequency of viral genotypic substitutions in subjects previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) who did not achieve or did not maintain SVR12</outcome_measure>
      <outcome_measure>Long-term progression of liver disease, as measured by the frequency of hepatic disease progression, all cause mortality, and liver-related mortality</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Brazil</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>Japan</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01492504</url>
  </study>
  <study rank="40">
    <nct_id>NCT01016912</nct_id>
    <title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-021</other_id>
    </other_ids>
    <first_received>November 19, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 17, 2015</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Sustained Virologic Response (SVR) at Weeks 4, 12, and 24</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01016912</url>
  </study>
  <study rank="41">
    <nct_id>NCT01017575</nct_id>
    <title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-022</other_id>
    </other_ids>
    <first_received>November 19, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>August 13, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>August 13, 2015</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 and Follow-up Week 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01017575</url>
  </study>
  <study rank="42">
    <nct_id>NCT01170962</nct_id>
    <title>Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>512</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-011</other_id>
      <other_id>2010-019378-34</other_id>
    </other_ids>
    <first_received>July 16, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>September 11, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 10, 2015</firstreceived_results_date>
    <acronym>HEPCAT</acronym>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With 24-week Sustained Virologic Response (SVR24)</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died On-treatment</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs) and Who Died During Follow-up Period</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants With Genotypic-1A Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures</outcome_measure>
      <outcome_measure>Number of Participants With Genotypic-1B Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Mexico</country>
      <country>Puerto Rico</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01170962</url>
  </study>
  <study rank="43">
    <nct_id>NCT01125189</nct_id>
    <title>Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">peg-interferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>558</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-010</other_id>
      <other_id>2010-018295-24</other_id>
    </other_ids>
    <first_received>May 17, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 13, 2015</firstreceived_results_date>
    <acronym>HEPCAT</acronym>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Sustained Virologic Response (SVR24)</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Who Died</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With 12-week Sustained Virologic Response (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Resistant Variants Associated With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Denmark</country>
      <country>Egypt</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Mexico</country>
      <country>Puerto Rico</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01125189</url>
  </study>
  <study rank="44">
    <nct_id>NCT02580474</nct_id>
    <title>The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir plus Asunaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Myeong Jun Song</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
      <collaborator>Soonchunhyang University Hospital</collaborator>
      <collaborator>Dankook University</collaborator>
      <collaborator>Chungnam National University Hospital</collaborator>
      <collaborator>Konyang University Hospital</collaborator>
      <collaborator>Eulji University Hospital</collaborator>
      <collaborator>Saint Vincent's Hospital, Korea</collaborator>
      <collaborator>Konkuk University Hospital</collaborator>
      <collaborator>Cheongju St. Mary's Hospital, Cheongju, Korea</collaborator>
      <collaborator>Severance Hospital</collaborator>
      <collaborator>Korea University Guro Hospital</collaborator>
      <collaborator>Eulji General Hospital</collaborator>
      <collaborator>The Catholic University of Korea</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-118</other_id>
    </other_ids>
    <first_received>October 16, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>the proportion of subjects with plasma HCV RNA levels below 15 IU/mL at Week 12 After End of Treatment</outcome_measure>
      <outcome_measure>To evaluate the percentage of subjects with Sustained Virologic Response at Week 12 After End of Treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with ALT normalization at each visit from the baseline</outcome_measure>
      <outcome_measure>Change in HCV RNA at each visit from the baseline</outcome_measure>
      <outcome_measure>Percentage of subjects who experience viral breakthrough at each visit from the baseline</outcome_measure>
      <outcome_measure>Percentage of subjects who shows Tolerability of Daclatasvir and Asunaprevir at each visit from</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02580474</url>
  </study>
  <study rank="45">
    <nct_id>NCT02098616</nct_id>
    <title>Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DCV/ASV/BMS-791325</intervention>
      <intervention type="Drug">DCV/ASV/BMS-791325 + RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Timothy Morgan, MD</lead_sponsor>
      <collaborator>VA Long Beach Healthcare System</collaborator>
      <collaborator>National Cancer Institute (NCI)</collaborator>
      <collaborator>Bristol-Myers Squibb</collaborator>
      <collaborator>Southern California Institute for Research and Education</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB #1285</other_id>
      <other_id>AI443-128</other_id>
    </other_ids>
    <first_received>March 25, 2014</first_received>
    <start_date>July 2014</start_date>
    <last_updated>July 10, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RHACE 1</acronym>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>Sustained virologic response</outcome_measure>
      <outcome_measure>Post treatment virologic response</outcome_measure>
      <outcome_measure>On treatment virologic response</outcome_measure>
      <outcome_measure>Virologic failure</outcome_measure>
      <outcome_measure>Day 2 positive predictive value</outcome_measure>
      <outcome_measure>Interferon lambda genotype and virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02098616</url>
  </study>
  <study rank="46">
    <nct_id>NCT02556086</nct_id>
    <title>A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-378</other_id>
      <other_id>2015-003467-12</other_id>
    </other_ids>
    <first_received>September 15, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>July 2017</completion_date>
    <last_updated>November 18, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with SVR12</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR12) rate</outcome_measure>
      <outcome_measure>Treatment safety measured by the number of incidence of serious adverse event (SAEs), discontinuations due to adverse event (AEs), Grade 3/4 AEs and Grade 3/4 clinical laboratory abnormalities through the end of treatment</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve HCV RNA &lt; LLOQ-TD/TND at each of the following Weeks: 1, 2, 4, 6, 8, EOT, post-treatment Week 4 in subjects on the 8-week regimen of DCV/SOF</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve HCV RNA &lt; LLOQ TND at each of the following Weeks: 1, 2, 4, 6, 8, end of treatment (EOT), in subjects on the 8-week regimen of DCV/SOF</outcome_measure>
      <outcome_measure>Proportion of subjects receiving cART who maintain HIV virologic suppression</outcome_measure>
      <outcome_measure>Proportion of subjects receiving cART who experience HIV virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02556086</url>
  </study>
  <study rank="47">
    <nct_id>NCT01389323</nct_id>
    <title>BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Peg-Interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>448</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-038</other_id>
    </other_ids>
    <first_received>July 6, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>September 19, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 17, 2015</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12) With rs12979860 Single Nucleotide Polymorphisms at Baseline in the Interleukin-28B Gene</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus (HCV) RNA Levels &lt;Lower Limit of Quantitation (LLOQ), Target Detected or Target Not Detected, at Specified Time Points</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus (HCV) RNA Levels &lt;Lower Limit of Quantitation (LLOQ), Target Not Detected, at Specified Time Points</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Treatment-related AEs, and Who Died</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Mississippi</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01389323</url>
  </study>
  <study rank="48">
    <nct_id>NCT01995266</nct_id>
    <title>Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>159</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-036</other_id>
    </other_ids>
    <first_received>November 21, 2013</first_received>
    <start_date>February 2014</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>July 21, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects who achieve Sustained Virologic Response (SVR) 24</outcome_measure>
      <outcome_measure>Proportion of treated subjects who achieve SVR12</outcome_measure>
      <outcome_measure>Safety, as measured by the frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR24 by the rs12979860 single nucleotide polymorphism (SNP) in the Interferon lambda 3 (IL28B) gene</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target not detected</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA &lt; LLOQ target detected or not detected</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Korea, Republic of</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01995266</url>
  </study>
  <study rank="49">
    <nct_id>NCT02097966</nct_id>
    <title>EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C</title>
    <recruitment open="Y">Available</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <study_designs/>
    <other_ids>
      <other_id>AI444-237</other_id>
    </other_ids>
    <first_received>March 25, 2014</first_received>
    <last_updated>November 19, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Austria</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02097966</url>
  </study>
  <study rank="50">
    <nct_id>NCT02473211</nct_id>
    <title>SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_SOF plus DCV treatment</other_id>
    </other_ids>
    <first_received>June 12, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>June 19, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after the end of treatment (SVR12)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02473211</url>
  </study>
  <study rank="51">
    <nct_id>NCT01866930</nct_id>
    <title>Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Lambda-1a</intervention>
      <intervention type="Drug">Daclatasvir (DCV)</intervention>
      <intervention type="Drug">Ribasphere (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-032</other_id>
      <other_id>2012-003280-22</other_id>
    </other_ids>
    <first_received>May 29, 2013</first_received>
    <start_date>July 2013</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>September 10, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DIMENSION</acronym>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Antiviral activity, as determined by the proportion of subjects with SVR12, defined as HCV RNA &lt;LLOQ (25 IU/mL), target detected or target not detected, for each treatment arm</outcome_measure>
      <outcome_measure>Proportion of subjects with Rapid virologic response (RVR) and Extended Rapid Virologic Response (eRVR), where RVR is defined as &lt;LLOQ target not detected at week 4 and eRVR defined as &lt;LLOQ target not detected at Weeks 4 and 12</outcome_measure>
      <outcome_measure>Proportion of subjects in each group/duration who achieve HCV RNA &lt;LLOQ target detected or not detected, at end of therapy (SVR24)</outcome_measure>
      <outcome_measure>Proportion of subjects with treatment emergent cytopenic abnormalities (anemia as defined by Hb &lt;10 g/dL, and/or neutropenia as defined by ANC &lt;750 mm3 and/or thrombocytopenia as defined by platelets &lt;50,000 mm3) during the treatment period</outcome_measure>
      <outcome_measure>Proportion of subjects with the following on treatment IFN-associated symptoms: flu-like symptoms (as defined by pyrexia or chills or pain) and musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)</outcome_measure>
      <outcome_measure>Frequency of deaths, serious adverse events (SAEs), discontinuations due to Adverse Events (AEs), dose reductions, and severity Grade 3/4 laboratory abnormalities</outcome_measure>
      <outcome_measure>Absolute and percent change from baseline in the CD4 cell count, lymphocyte cell count, and platelet count</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Argentina</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Mexico</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01866930</url>
  </study>
  <study rank="52">
    <nct_id>NCT01795911</nct_id>
    <title>Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Lambda</intervention>
      <intervention type="Drug">Ribasphere</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-008 (Substudy Part C)</other_id>
      <other_id>2010-022568-11</other_id>
    </other_ids>
    <first_received>February 20, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>D-LITE</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Antiviral activity, as determined by the proportion of non-cirrhotic HCV GT-1b subjects with 12-week sustained virologic response (SVR12), defined as HCV RNA &lt; LLOQ target detected or not detected</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with eRVR, defined as HCV RNA &lt; LLOQ target not detected</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with treatment-emergent cytopenic abnormalities (anemia as defined by Hb &lt; 10 g/dL, and/or neutropenia as defined by ANC &lt; 750 mm3, and/or thrombocytopenia as defined by platelets &lt; 50,000 mm3) on treatment</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with on-treatment (maximum of 12 weeks) interferon-associated flu-like symptoms (pyrexia or chills or pain)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with on-treatment (maximum of 12 weeks) interferon-associated musculoskeletal symptoms (arthralgia or myalgia or back pain)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with SVR24, defined as HCV RNA &lt; LLOQ target detected or not detected</outcome_measure>
      <outcome_measure>Frequency of deaths among non-cirrhotic HCV GT-1b subjects through the end of follow-up (maximum of 60 weeks)</outcome_measure>
      <outcome_measure>Frequency of Serious adverse events (SAEs) among non-cirrhotic HCV GT-1b subjects through the end of follow-up (maximum of 60 weeks)</outcome_measure>
      <outcome_measure>Frequency of drug related Adverse events (AEs) among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Frequency of dose reductions and discontinuations due to AEs among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Frequency of treatment emergent laboratory abnormalities among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with interferon-associated constitutional symptoms (fatigue or asthenia) through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with interferon-associated neurologic symptoms (headache or dizziness) through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with psychiatric symptoms (depression or irritability or insomnia) through the end of treatment (maximum of 12 weeks)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01795911</url>
  </study>
  <study rank="53">
    <nct_id>NCT01359644</nct_id>
    <title>Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PSI-7977</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
      <collaborator>Pharmasset</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-040</other_id>
    </other_ids>
    <first_received>May 23, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 21, 2015</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Post Treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Post Treatment Week 24 (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough During the Treatment Period</outcome_measure>
      <outcome_measure>Percentage of Participants Who Experienced Viral Relapse During Follow-up Period</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) RNA at Follow-up Week 24</outcome_measure>
      <outcome_measure>Number of Participants Who Died and With Serious Adverse Events (SAEs) and Grade 3-4 Adverse Events (AEs), During the Treatment Period Prior to Addition of Rescue Therapy</outcome_measure>
      <outcome_measure>Number of Participants Who Died and With Serious Adverse Events (SAEs), Grade 3-4 Adverse Events (AEs), and Grade 3-4 Abnormalities on Laboratory Test Results During Follow-up Period</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01359644</url>
  </study>
  <study rank="54">
    <nct_id>NCT00546715</nct_id>
    <title>A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>95</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-002</other_id>
    </other_ids>
    <first_received>October 17, 2007</first_received>
    <start_date>November 2007</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>August 10, 2015</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died</outcome_measure>
      <outcome_measure>Number of Participants With Clinically Significant Change From Baseline in Vital Sign Measurements and Physical Examination Findings</outcome_measure>
      <outcome_measure>Number of Participants With Marked Abnormalities in Laboratory Findings</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) and Observed Plasma Concentration at 12 Hours (C-12) and 24 Hours (C-24)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-T]), Area Under the Plasma Concentration-time Curve From Time Zero (AUC[INF]) Extrapolated to Infinite Time</outcome_measure>
      <outcome_measure>Time to Reach Maximum Plasma Concentration (Tmax)</outcome_measure>
      <outcome_measure>Plasma Half-life (T-half)</outcome_measure>
      <outcome_measure>Apparent Total Body Clearance (CLT/F)</outcome_measure>
      <outcome_measure>Decline From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Time to Reach Maximum Decline in Plasma Hepatitis C Virus RNA Levels From Baseline</outcome_measure>
      <outcome_measure>Change From Baseline in Heart Rate to Day 7 or Discharge</outcome_measure>
      <outcome_measure>Change From Baseline in Electrocardiogram (ECG) Parameters (PR, QRS, QT, and QTc Intervals) to Day 7 or Discharge</outcome_measure>
      <outcome_measure>Change From Baseline in Blood Pressure to Day 7 or Discharge</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>New Jersey</state>
      <state>Pennsylvania</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00546715</url>
  </study>
  <study rank="55">
    <nct_id>NCT01257204</nct_id>
    <title>Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>196</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-031</other_id>
      <other_id>2010-022408-28</other_id>
    </other_ids>
    <first_received>December 1, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>August 5, 2015</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 24 (SVR24) for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 24 (SVR24) for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR) at Week 4 for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR) at Week 4 for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Complete Early Virologic Response (cEVR) at Week 12 for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Complete Early Virologic Response (cEVR) at Week 12 for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 12 (SVR12) for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 12 (SVR12) for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Number of Participants With Virologic Failure for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Number of Participants With Virologic Failure for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Treatment-related AEs and Who Died During Treatment Period</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Who Died During Follow-up Period</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
      <state>Oklahoma</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01257204</url>
  </study>
  <study rank="56">
    <nct_id>NCT00983957</nct_id>
    <title>Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">Ortho Tri-Cyclen®</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>47</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-020</other_id>
    </other_ids>
    <first_received>September 23, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>September 16, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 18, 2015</firstreceived_results_date>
    <primary_completion_date>February 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol</outcome_measure>
      <outcome_measure>Area Under the Concentration-Time Curve (AUC) in 1 Dosing Interval of Ethinyl Estradiol</outcome_measure>
      <outcome_measure>Time of Maximum Observed Plasma Concentration of Ethinyl Estradiol</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration of Norelgestromin</outcome_measure>
      <outcome_measure>Area Under the Concentration-Time Curve in 1 Dosing Interval of Norelgestromin</outcome_measure>
      <outcome_measure>Time of Maximum Observed Plasma Concentration of Norelgestromin</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration of Norgestrel</outcome_measure>
      <outcome_measure>Area Under the Concentration-Time Curve in 1 Dosing Interval of Norgestrel</outcome_measure>
      <outcome_measure>Time of Maximum Observed Plasma Concentration of Norgestrel</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Who Died</outcome_measure>
      <outcome_measure>Number of Participants With Laboratory Test Abnormalities</outcome_measure>
      <outcome_measure>Number of Participants Demonstrating a Clinically Meaningful Effect in Vital Signs</outcome_measure>
      <outcome_measure>Number of Participants Demonstrating a Clinically Meaningful Effect in ECG Parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00983957</url>
  </study>
  <study rank="57">
    <nct_id>NCT01497834</nct_id>
    <title>A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052 (Daclatasvir)</intervention>
      <intervention type="Drug">BMS-650032 (Asunaprevir)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>224</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-026</other_id>
    </other_ids>
    <first_received>December 2, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Antiviral activity, as determined by the proportion of subjects with SVR24</outcome_measure>
      <outcome_measure>Antiviral activity, as determined by the proportion of subjects who achieve Hepatitis C virus (HCV) ribonucleic acid (RNA) below lower limit of quantitation (LLOQ) target detected or not detected</outcome_measure>
      <outcome_measure>Antiviral activity, as determined by the proportion of subjects who achieve HCV RNA below LLOQ, target not detected</outcome_measure>
      <outcome_measure>Safety, as measured by the frequency of serious adverse events (SAEs), discontinuations due to adverse events (AEs), AEs by intensity and laboratory abnormalities by toxicity grade</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR24 by IL28B status [CC, CT, or TT genotype at the IL28B rs12979860 single nucleotide polymorphisms (SNP)]</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01497834</url>
  </study>
  <study rank="58">
    <nct_id>NCT01492426</nct_id>
    <title>Study Comparing BMS-790052 (Daclatasvir) to Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Untreated Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052 (Daclatasvir)</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>605</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-052</other_id>
      <other_id>2011-004237-14</other_id>
    </other_ids>
    <first_received>December 13, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>May 5, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>COMMAND-3</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of genotype 1b patients with SVR12, defined as HCV RNA less than limit of quantitation at follow-up Week 12 in each group</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with hemoglobin value less than 10 g/dL</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with rash events</outcome_measure>
      <outcome_measure>Proportion of genotype1b patients with HCV RNA undetectable Week 12</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with HCV RNA undetectable Week 4</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with HCV RNA undetectable Weeks 4 and 12</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with SVR24, defined as HCV RNA &lt; Limit of Quantification (LOQ) at follow-up Week 24 for each cohort</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with SVR12 based on IL28B rs12979860 Single nucleotide polymorphism (SNP) genotype (CC or non-CC)</outcome_measure>
      <outcome_measure>Proportion of genotype 1a patients with SVR12 defined as HCV RNA &lt; LOQ at follow-up Week 12 for each cohort</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Brazil</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01492426</url>
  </study>
  <study rank="59">
    <nct_id>NCT01471574</nct_id>
    <title>Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052 (Daclatasvir)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peg-Interferon alfa 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>301</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-043</other_id>
      <other_id>2011-003067-30</other_id>
    </other_ids>
    <first_received>November 4, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>February 6, 2015</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with SVR12, defined as HCV RNA &lt; LLOQ, target detected or not detected at post-treatment Week 12</outcome_measure>
      <outcome_measure>Proportion of subjects with Genotype 1 infection who achieve HCV RNA &lt; LLOQ , target detected or not detected</outcome_measure>
      <outcome_measure>Proportion of subjects with Genotype 1 infection who achieve HCV RNA &lt; LLOQ, target not detected</outcome_measure>
      <outcome_measure>Safety, as measured by the frequency of SAEs and discontinuations due to AEs</outcome_measure>
      <outcome_measure>Proportion of subjects who are receiving HAART and who maintain their HIV RNA &lt; 40 copies/mL and the proportion of subjects who experience confirmed HIV RNA ≥ 400 copies/mL at end of treatment for subjects who are receiving HAART</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12 by rs12979860 Single nucleotide polymorphism (SNP) in the IL28B gene</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01471574</url>
  </study>
  <study rank="60">
    <nct_id>NCT01725542</nct_id>
    <title>Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV-HIV Co-Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC30 QUADRIH</other_id>
      <other_id>2012-002589-11</other_id>
    </other_ids>
    <first_received>October 22, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>September 5, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>QUADRIH</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV Sustained virological response rate</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability</outcome_measure>
      <outcome_measure>Kinetics of HCV Virological response</outcome_measure>
      <outcome_measure>Immunological and virological evolution of HIV infection</outcome_measure>
      <outcome_measure>Evolution of cirrhosis (for cirrhotic patients)</outcome_measure>
      <outcome_measure>Number of Participants with HIV and non HIV related clinical events</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) of ribavirin</outcome_measure>
      <outcome_measure>Pharmacokinetics of Antiretroviral drugs</outcome_measure>
      <outcome_measure>Pharmacokinetics of Asunaprevir and Daclatasvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01725542</url>
  </study>
  <study rank="61">
    <nct_id>NCT01573351</nct_id>
    <title>Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Peg-interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>398</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-029</other_id>
      <other_id>2011-005422-21</other_id>
    </other_ids>
    <first_received>April 5, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Hallmark QUAD</acronym>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of genotype 1 subjects with SVR12, defined as HCV RNA &lt; LOQ at post-treatment Week 12, for all subjects infected with HCV genotype 1</outcome_measure>
      <outcome_measure>On-treatment safety, as measured by frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs) through the end of treatment</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12 (HCV RNA &lt; LOQ at post-treatment Week 12) by the rs12979860 single nucleotide polymorphisms (SNP) in the IL28 gene</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA undetectable</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA &lt; LOQ</outcome_measure>
      <outcome_measure>Proportion of patients with SVR12 (HCV RNA &lt; LOQ at post-treatment Week 12) for HCV genotype 4 subjects</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Argentina</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
      <country>Netherlands</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01573351</url>
  </study>
  <study rank="62">
    <nct_id>NCT01051414</nct_id>
    <title>An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-650032</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-017</other_id>
    </other_ids>
    <first_received>January 15, 2010</first_received>
    <start_date>April 2010</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part 1: To assess safety and tolerability based on 4 weeks safety data, as measured by related serious adverse events (SAEs) and discontinuations due to related AEs</outcome_measure>
      <outcome_measure>Part 2: To determine the proportion of subjects who achieve SVR12 (i.e., HCV RNA &lt; 15 IU/mL at follow-up Week 12)</outcome_measure>
      <outcome_measure>The safety of co-administration of BMS-790052 + BMS-650032 as measured by the frequency of SAEs, discontinuations due to AEs, and Grade 3 - 4 laboratory abnormalities</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve RVR (defined as HCV RNA &lt; 15 IU/mL</outcome_measure>
      <outcome_measure>The proportion of subjects with extended rapid virologic response (eRVR), defined as HCV RNA &lt; 15 IU/mL</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve SVR24 (defined as HCV RNA &lt; 15 IU/mL</outcome_measure>
      <outcome_measure>Resistant variants associated with clinical failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01051414</url>
  </study>
  <study rank="63">
    <nct_id>NCT02292966</nct_id>
    <title>Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DCV/ASV/BCV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1304</other_id>
    </other_ids>
    <first_received>September 25, 2014</first_received>
    <start_date>June 2015</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>April 28, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HEPCOG-II</acronym>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Neurocognitive functioning</outcome_measure>
      <outcome_measure>Brain metabolite concentrations</outcome_measure>
      <outcome_measure>NAA metabolite concentration in the brain</outcome_measure>
      <outcome_measure>Cho metabolite concentration in the brain</outcome_measure>
      <outcome_measure>Cr metabolite concentration in the brain</outcome_measure>
      <outcome_measure>MLO metabolite concentration in the brain</outcome_measure>
      <outcome_measure>Glx metabolite concentration in the brain</outcome_measure>
      <outcome_measure>Change in neurocognitive functioning compared between subjects with and without sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Change in brain metabolite concentrations compared between subjects with and without sustained virological response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02292966</url>
  </study>
  <study rank="64">
    <nct_id>NCT01973049</nct_id>
    <title>UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">BMS-791325</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo matching Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>202</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-113</other_id>
      <other_id>2013-002458-66</other_id>
    </other_ids>
    <first_received>October 25, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects in each of the naive arms with sustained virologic response (SVR12)</outcome_measure>
      <outcome_measure>Proportion of treated subjects in each of the experienced arms with SVR12</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm who achieve HCV RNA &lt; LOQ TD/TND</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm who achieve HCV RNA &lt; LOQ TND</outcome_measure>
      <outcome_measure>Safety as measured by frequency of Serious Adverse Events(SAEs)and discontinuations due to Adverse Events(AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects with anemia defined as Hg &lt; 10 g/dL on-treatment and Hg ≥ 10 g/dL at baseline in each arm within each cohort</outcome_measure>
      <outcome_measure>Differences in rates of selected Grade 3 - 4 laboratory test result abnormalities</outcome_measure>
      <outcome_measure>Proportion of subjects achieving SVR12 associated with HCV geno subtype 1a vs 1b</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm achieving SVR12 associated with IL28B rs12979860 single nucleotide polymorphism(SNP) status (CC genotype or non-CC genotype)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01973049</url>
  </study>
  <study rank="65">
    <nct_id>NCT01581203</nct_id>
    <title>Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir (ASV)</intervention>
      <intervention type="Drug">Daclatasvir (DCV)</intervention>
      <intervention type="Drug">Pegylated-interferon alfa 2a (PegIFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>748</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-028</other_id>
      <other_id>2011-005446-35</other_id>
    </other_ids>
    <first_received>April 18, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Hallmark DUAL</acronym>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects with SVR12, defined as HCV RNA &lt; LOQ at post treatment Week 12, for subjects who are prior null or partial responders to P/R or are treatment-naive</outcome_measure>
      <outcome_measure>Proportion of treated subjects with SVR12, defined as HCV RNA &lt; LOQ at post-treatment Week 12, for subjects who are intolerant or ineligible to P/R</outcome_measure>
      <outcome_measure>On treatment safety, as measured by frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Differences in rates of selected grade 3-4 laboratory abnormalities during the first 12 weeks between treatments (ASV + DCV vs PBO) for naive subjects</outcome_measure>
      <outcome_measure>Proportion of genotype 1b subjects with SVR12 (HCV RNA &lt; LOQ at post treatment Week 12) by the rs12979860 single nucleotide polymorphisms (SNP) in the IL28B gene for each cohort</outcome_measure>
      <outcome_measure>Proportion of genotype 1b subjects with HCV RNA undetectable</outcome_measure>
      <outcome_measure>Proportion of genotypes 1b subjects with HCV RNA &lt; LOQ</outcome_measure>
      <outcome_measure>Proportion of subjects with anemia</outcome_measure>
      <outcome_measure>Proportion of subjects with rash</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Ireland</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01581203</url>
  </study>
  <study rank="66">
    <nct_id>NCT01741545</nct_id>
    <title>Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated-Interferon-lambda</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-030</other_id>
      <other_id>2012-003463-22</other_id>
    </other_ids>
    <first_received>December 3, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>March 16, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MAGNITUDE</acronym>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who achieve SVR12 (HCV RNA &lt; LLOQ target not detected)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve Rapid virologic response (RVR) [HCV RNA &lt; LLOQ target not detected at Week 4]</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve Complete early virologic response (cEVR) [HCV RNA &lt; LLOQ target not detected at Week 12]</outcome_measure>
      <outcome_measure>Proportion of subjects who have HCV RNA &lt; LLOQ target not detected at Week 24</outcome_measure>
      <outcome_measure>Proportion of subjects with treatment emergent cytopenic abnormalities through end of treatment (Week 12 for Genotype-2, -3 and Week 24 for Genotype-1b, -4)</outcome_measure>
      <outcome_measure>Proportion of subjects who experience on-treatment Interferon (IFN)-associated symptoms such as flu-like systems or musculoskeletal symptoms</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR24 by treatment group</outcome_measure>
      <outcome_measure>Proportion of subjects with serious adverse events (SAEs), discontinuation due to adverse events (AEs) and dose reductions through end of follow-up (maximum of 60 weeks for Genotype-2, -3 and 72 weeks for Genotype-1b, -4)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>France</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>Pennsylvania</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01741545</url>
  </study>
  <study rank="67">
    <nct_id>NCT02124044</nct_id>
    <title>Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir and Dalatasvir</intervention>
      <intervention type="Drug">Daclatasvir and Asunaprevir, with or without BMS-791325</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institutes of Health Clinical Center (CC)</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>140065</other_id>
      <other_id>14-CC-0065</other_id>
    </other_ids>
    <first_received>April 25, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The incidence of grade 3 and 4 adverse events (AEs) followingtreatment with DCV/ASV or DCV/ASV/BMS-791325 in HIV-HCV coinfected subjects</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve SVR12</outcome_measure>
      <outcome_measure>Log change in HCV response</outcome_measure>
      <outcome_measure>The association between HIV Viral load &amp; lt; 40 copies/mL but detectable vs. undetectable while on therapy and HIV virologic failure or HIV VL blips.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02124044</url>
  </study>
  <study rank="68">
    <nct_id>NCT00904059</nct_id>
    <title>Drug-Drug Interaction Study in Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">BMS-790052</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-009</other_id>
    </other_ids>
    <first_received>April 21, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>January 6, 2011</last_updated>
    <last_verified>December 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacokinetic parameters including AUC (TAU) Cmax and Cmin</outcome_measure>
      <outcome_measure>To assess the safety, tolerability, and fractional excretion of sodium when BMS-709952 and BMS-650032 are co-administered</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00904059</url>
  </study>
  <study rank="69">
    <nct_id>NCT01012895</nct_id>
    <title>Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">Pegylated-interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>215</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-011</other_id>
      <other_id>2010-024637-23</other_id>
    </other_ids>
    <first_received>November 12, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatitis C virus (HCV) ribonucleic acid (RNA) levels in subjects' blood before, during and after treatment</outcome_measure>
      <outcome_measure>Safety assessments will be based on medical review of the frequency of SAEs and AEs, discontinuations due to AEs, and abnormalities observed from vital sign and ECG measurements, physical examinations and clinical laboratory results</outcome_measure>
      <outcome_measure>Pharmacokinetic parameter maximum observed concentration [Cmax] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</outcome_measure>
      <outcome_measure>Pharmacokinetic parameter trough observed concentration [Cmin] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</outcome_measure>
      <outcome_measure>Pharmacokinetic parameter time of maximum observed concentration [Tmax] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</outcome_measure>
      <outcome_measure>Pharmacokinetic parameter area under the concentration-time curve in one dosing interval [AUC(TAU)] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01012895</url>
  </study>
  <study rank="70">
    <nct_id>NCT02045966</nct_id>
    <title>Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cocktail</intervention>
      <intervention type="Drug">DCV 3DAA FDC</intervention>
      <intervention type="Drug">BMS-791325</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-021</other_id>
    </other_ids>
    <first_received>January 23, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>June 16, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] for each cocktail CYP and transporter probe substrate</outcome_measure>
      <outcome_measure>Maximum observed concentration (Cmax) for each cocktail CYP and transporter probe substrate</outcome_measure>
      <outcome_measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] for each cocktail CYP and transporter probe substrate</outcome_measure>
      <outcome_measure>Cmax for the measured metabolites of the cocktail CYP and transporter probe substrates</outcome_measure>
      <outcome_measure>AUC(0-T) for the measured metabolites of the cocktail CYP and transporter probe substrates</outcome_measure>
      <outcome_measure>AUC(INF) for the measured metabolites of the cocktail CYP and transporter probe substrates</outcome_measure>
      <outcome_measure>Time of maximum observed concentration (Tmax) for each cocktail CYP and transporter probe substrate and their metabolites</outcome_measure>
      <outcome_measure>Half life (T-HALF) for each cocktail CYP and transporter probe substrate and their metabolites</outcome_measure>
      <outcome_measure>Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax) for each cocktail CYP and transporter probe substrate and their metabolites</outcome_measure>
      <outcome_measure>Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight [MR_AUC(0-T)] for each cocktail CYP and transporter probe substrate and their metabolites</outcome_measure>
      <outcome_measure>Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight [MR_AUC(INF)] for each cocktail CYP and transporter probe substrate and their metabolites</outcome_measure>
      <outcome_measure>Apparent total body clearance (CLT/F) for each cocktail CYP and transporter probe substrate</outcome_measure>
      <outcome_measure>Cmax for Daclatasvir, Asunaprevir, BMS-791325, and the metabolite, BMS- 794712 at steady state</outcome_measure>
      <outcome_measure>Tmax for Daclatasvir, Asunaprevir, BMS-791325, and the metabolite, BMS- 794712 at steady state</outcome_measure>
      <outcome_measure>Concentration at 12 hours (C12) for Daclatasvir, Asunaprevir, BMS-791325, and the metabolite, BMS- 794712 at steady state</outcome_measure>
      <outcome_measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] for Daclatasvir, Asunaprevir, BMS-791325, and the metabolite, BMS- 794712 at steady state</outcome_measure>
      <outcome_measure>MR_Cmax for BMS-791325 and the metabolite, BMS-794712</outcome_measure>
      <outcome_measure>Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight [MR_AUC(TAU)] for BMS-791325 and the metabolite, BMS-794712</outcome_measure>
      <outcome_measure>Trough observed plasma concentration (Ctrough) for Daclatasvir, Asunaprevir, BMS-791325, and the metabolite, BMS-794712</outcome_measure>
      <outcome_measure>Safety measured by the occurrence of AEs and SAEs, abnormalities in vital sign measurements exceeding pre-defined thresholds, findings on ECG measurements and physical examinations, and marked abnormalities in clinical laboratory test results</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02045966</url>
  </study>
  <study rank="71">
    <nct_id>NCT02103569</nct_id>
    <title>Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">FDC of Daclatasvir, Asunaprevir and BMS-791325</intervention>
      <intervention type="Drug">FDC of Norethindrone and Ethinyl Estradiol</intervention>
      <intervention type="Drug">BMS-791325</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-016</other_id>
    </other_ids>
    <first_received>April 1, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>August 13, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area under the concentration versus time curve in 1 dosing interval (AUC (TAU)) of Ethinyl Estradiol and Norethindrone</outcome_measure>
      <outcome_measure>Maximum observed plasma concentration (Cmax) of Ethinyl Estradiol and Norethindrone</outcome_measure>
      <outcome_measure>Dose-normalized area under the concentration versus time curve in 1 dosing interval (AUC (TAU)) of Ethinyl Estradiol and Norethindrone</outcome_measure>
      <outcome_measure>Dose-normalized maximum observed plasma concentration (Cmax) of Ethinyl Estradiol and Norethindrone</outcome_measure>
      <outcome_measure>Time of maximum observed plasma concentration (Tmax) of Ethinyl Estradiol and Norethindrone</outcome_measure>
      <outcome_measure>Safety measured by occurrence of Adverse events (AEs), serious AEs and AEs leading to discontinuation</outcome_measure>
      <outcome_measure>Safety measured by abnormalities in vital sign measurements</outcome_measure>
      <outcome_measure>Safety measured by findings on Electrocardiogram (ECG) measurements and physical examinations</outcome_measure>
      <outcome_measure>Safety measured by marked abnormalities in clinical laboratory test results</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02103569</url>
  </study>
  <study rank="72">
    <nct_id>NCT02175966</nct_id>
    <title>Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DCV/ASV/BMS-791325</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Peginterferon α-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-131</other_id>
    </other_ids>
    <first_received>June 25, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>FOURward</acronym>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects with SVR12, defined as HCV RNA &lt; LLOQ target detected or target not detected (LLOQ TD/TND) for each treatment arm</outcome_measure>
      <outcome_measure>On-treatment safety, as measured by frequency of deaths, SAEs, discontinuations due to AEs, and Grade 3/4 laboratory abnormalities (hematologic and liver function, based on DAIDs criteria) by each arm and overall</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm who achieve HCV RNA &lt;LLOQ TD/TND</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm who achieve HCV RNA &lt;LLOQ TND</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm achieving SVR12 associated with HCV geno subtype 1a vs 1b</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm achieving SVR12 associated with interleukin-28B (IL28B) rs12979860 SNP status (CC genotype or non-CC genotype)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02175966</url>
  </study>
  <study rank="73">
    <nct_id>NCT02368522</nct_id>
    <title>Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-259</other_id>
    </other_ids>
    <first_received>February 12, 2015</first_received>
    <start_date>December 2014</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>November 19, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Quantify effectiveness of daclatasvir (DCV) containing regimen overall and in subgroups (GT1, non GT1 and cirrhotic patients) by measuring sustained virologic response (SVR12)</outcome_measure>
      <outcome_measure>SVR12 in patients treated with DCV-containing regimens in real-life by treatment regimen, genotype, cirrhosis stage, HCV-treatment experience, HIV coinfection, and previous LTx (if present)</outcome_measure>
      <outcome_measure>Proportion of patients on DCV-containing regimens achieving SVR12 in real-life compared with SVR12 rates in clinical trials</outcome_measure>
      <outcome_measure>Safety of DCV-containing regimens in real-life measured by the incidence of (S)AEs and the incidence leading to treatment discontinuation</outcome_measure>
      <outcome_measure>Demographic and clinical characteristics and treatment patterns of patients starting a new HCV treatment regimen (with or without DCV), overall and by treatment regimen,GT,cirrhosis stage,HCV-treatment experience,HIV co-infection,and previous LTx</outcome_measure>
      <outcome_measure>Comparison of demographic and clinical characteristics of patients starting a new HCV treatment regimen (with or without DCV) by treatment regimen and to identify factors associated with the initiation of different regimens</outcome_measure>
      <outcome_measure>SVR 24 in patients treated with DCV-containing regimens in real-life clinical care, change of Child-Pugh Score and Metavir score as well as change of patient related outcomes (EQ-5D and SF-36 questionnaires measuring quality of life)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02368522</url>
  </study>
  <study rank="74">
    <nct_id>NCT02095860</nct_id>
    <title>Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DCV 3DAA FDC</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-111</other_id>
    </other_ids>
    <first_received>March 21, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>October 9, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum observed plasma concentration (Cmax) of DCV, ASV and BMS-791325</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of DCV, ASV and BMS-791325</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] for DCV, ASV and BMS-791325</outcome_measure>
      <outcome_measure>Time of maximum observed plasma concentration (Tmax) for DCV, ASV and BMS-791325</outcome_measure>
      <outcome_measure>Terminal plasma half life (T-HALF) for DCV, ASV and BMS-791325</outcome_measure>
      <outcome_measure>AUC(0-T) for BMS-794712</outcome_measure>
      <outcome_measure>AUC(INF) for BMS-794712</outcome_measure>
      <outcome_measure>Cmax for BMS-794712</outcome_measure>
      <outcome_measure>Tmax for BMS-794712</outcome_measure>
      <outcome_measure>T-HALF for BMS-794712</outcome_measure>
      <outcome_measure>Safety measured by incidence of adverse event (AEs), serious AEs (SAEs) and AEs leading to discontinuation</outcome_measure>
      <outcome_measure>Safety measured by abnormalities in vital sign measurements</outcome_measure>
      <outcome_measure>Safety measured by findings on electrocardiograms (ECG) measurements and physical examinations</outcome_measure>
      <outcome_measure>Safety measured by marked abnormalities in clinical laboratory test results</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02095860</url>
  </study>
  <study rank="75">
    <nct_id>NCT02555943</nct_id>
    <title>DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>HBV Coinfection</condition>
      <condition>Hepatitis B Reactivation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ledipasvir/Sofosbuvir</intervention>
      <intervention type="Drug">Sofosbuvir and Daclatasvir</intervention>
      <intervention type="Drug">Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir</intervention>
      <intervention type="Drug">Entecavir</intervention>
      <intervention type="Drug">Tenofovir disoproxil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
      <collaborator>Nanfang Hospital of Southern Medical University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_DASCO</other_id>
    </other_ids>
    <first_received>September 20, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>September 20, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DASCO</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants who experience virological breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants who experience virological rebound</outcome_measure>
      <outcome_measure>Proportion of participant who experience biochemical rebound</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02555943</url>
  </study>
  <study rank="76">
    <nct_id>NCT02161939</nct_id>
    <title>A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C</title>
    <recruitment open="Y">Available</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir (BMS-790052)</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <study_designs/>
    <other_ids>
      <other_id>AI444-257</other_id>
    </other_ids>
    <first_received>June 10, 2014</first_received>
    <last_updated>November 19, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02161939</url>
  </study>
  <study rank="77">
    <nct_id>NCT02470858</nct_id>
    <title>Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF+ASV</intervention>
      <intervention type="Drug">SOF+DCV+SMV</intervention>
      <intervention type="Drug">SOF+DCV+ASV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
      <collaborator>Emory University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_Triple Therapy_1</other_id>
    </other_ids>
    <first_received>June 5, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>August 6, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment.</outcome_measure>
      <outcome_measure>HCV RNA levels and change during and after treatment.</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic breakthrough and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02470858</url>
  </study>
  <study rank="78">
    <nct_id>NCT02082808</nct_id>
    <title>Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection, Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DTG</intervention>
      <intervention type="Drug">DCV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ViiV Healthcare</lead_sponsor>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>201102</other_id>
    </other_ids>
    <first_received>March 6, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>June 5, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Composite of PK parameters of DTG following DTG 50 mg q24h administration with and without DCV 60mg q24h</outcome_measure>
      <outcome_measure>Composite of PK parameters of DCV following administration of DCV 60 mg q24h with and without DTG 50 mg q24h</outcome_measure>
      <outcome_measure>Safety and Tolerability of DTG and DCV as assessed by adverse event</outcome_measure>
      <outcome_measure>Safety and Tolerability of DTG and DCV as assessed by concurrent medication</outcome_measure>
      <outcome_measure>Safety and Tolerability of DTG and DCV as assessed by clinical laboratory</outcome_measure>
      <outcome_measure>Safety and Tolerability of DTG and DCV as assessed by ECG</outcome_measure>
      <outcome_measure>Safety and Tolerability of DTG and DCV as assessed by vital signs assessments</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Kansas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02082808</url>
  </study>
  <study rank="79">
    <nct_id>NCT02250001</nct_id>
    <title>Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-244</other_id>
    </other_ids>
    <first_received>September 24, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>July 3, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The real-world safety, specifically the incidence rates of hepatic toxicity, pyrexia, and resistance, of Daclatasvir/Asunaprevir (DCV/ASV) dual therapy in Japanese patients chronically infected with Hepatitis C virus Genotype 1 (HCV GT-1)</outcome_measure>
      <outcome_measure>Antiviral activity as determined by the proportion of patients with sustained virologic response at 24 weeks post-treatment Sustained virologic response at 24 weeks post-treatment (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02250001</url>
  </study>
  <study rank="80">
    <nct_id>NCT02175602</nct_id>
    <title>Study of Drug Combination on Pharmacokinetics in Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Escitalopram</intervention>
      <intervention type="Drug">Sertraline</intervention>
      <intervention type="Drug">DCV 3DAA FDC</intervention>
      <intervention type="Drug">BMS-791325</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-116</other_id>
    </other_ids>
    <first_received>June 24, 2014</first_received>
    <start_date>June 2014</start_date>
    <last_updated>February 9, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Serial blood samples for plasma SSRI (selective serotonin reuptake inhibitor) of escitalopram or sertraline</outcome_measure>
      <outcome_measure>Serial blood samples for determination of plasma concentrations of DCV (daclatasvir), ASV (asunaprevir), BMS-791325, and the metabolite BMS-794712</outcome_measure>
      <outcome_measure>Safety assessments based on review of adverse events, vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02175602</url>
  </study>
  <study rank="81">
    <nct_id>NCT02576314</nct_id>
    <title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF+DCV</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_HCV G3 Study</other_id>
    </other_ids>
    <first_received>October 12, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>October 13, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks (SVR12) after discontinuation of therapy</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment</outcome_measure>
      <outcome_measure>HCV RNA levels and change during and after treatment</outcome_measure>
      <outcome_measure>Treatment adherence</outcome_measure>
      <outcome_measure>Change in health related quality of life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02576314</url>
  </study>
  <study rank="82">
    <nct_id>NCT02170727</nct_id>
    <title>A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DCV/ASV/BMS-791325</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>169</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-123</other_id>
    </other_ids>
    <first_received>June 20, 2014</first_received>
    <start_date>June 2014</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>UNITY 4</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects with SVR12 in the naive cohort</outcome_measure>
      <outcome_measure>Proportion of treated subjects with SVR12 in the IFNα experienced cohort</outcome_measure>
      <outcome_measure>Proportion of subjects in each cohort who achieve HCV RNA &lt; LOQ TD/TND</outcome_measure>
      <outcome_measure>Proportion of subjects in each cohort who achieve HCV RNA &lt; LOQ TND</outcome_measure>
      <outcome_measure>Safety in each cohort, as measured by frequency of serious adverse events(SAEs), discontinuations due to AEs, and selected Grade 3-4 laboratory abnormalities (including hematologic and liver function, based on DAIDS criteria)</outcome_measure>
      <outcome_measure>Proportion of subjects with anemia defined as Hb &lt; 10 g/dL on-treatment who have Hb ≥10 g/dL at baseline in each cohort</outcome_measure>
      <outcome_measure>Proportion of subjects in each cohort achieving SVR12 associated with hepatitis C virus (HCV) genotype subtype 1a vs 1b</outcome_measure>
      <outcome_measure>Proportion of subjects in each cohort achieving SVR12 associated with IL28B rs12979860 Single Nucleotide Polymorphisms (SNP) status (CC genotype or non CC genotype)</outcome_measure>
      <outcome_measure>Proportion of cirrhotic and non cirrhotic subjects who achieve SVR12</outcome_measure>
      <outcome_measure>Safety of non-cirrhotic vs cirrhotic subjects, as measured by the frequency of SAEs, discontinuations due to adverse events (AEs), and selected Grade 3 4 laboratory abnormalities (including hematologic and liver function, based on DAIDS criteria)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
      <country>Russian Federation</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02170727</url>
  </study>
  <study rank="83">
    <nct_id>NCT02531269</nct_id>
    <title>Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
      <collaborator>Basel Institute of Clinical Epidemiology (BICE)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-319</other_id>
    </other_ids>
    <first_received>August 11, 2015</first_received>
    <start_date>March 2015</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>SVR4</outcome_measure>
      <outcome_measure>SVR24</outcome_measure>
      <outcome_measure>On-treatment Virological response at week 4 assessed by measuring viral load</outcome_measure>
      <outcome_measure>Virological response at the end of treatment (EOT) assessed by measuring viral load</outcome_measure>
      <outcome_measure>The occurrence of virological failure (on-treatment and relapse) assessed by measuring viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02531269</url>
  </study>
  <study rank="84">
    <nct_id>NCT02469012</nct_id>
    <title>Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Combination #1</intervention>
      <intervention type="Drug">Combination #2</intervention>
      <intervention type="Drug">Combination #3</intervention>
      <intervention type="Drug">Combination #4</intervention>
      <intervention type="Drug">Combination #5</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Wuerzburg</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Screening</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>228/14</other_id>
    </other_ids>
    <first_received>May 5, 2015</first_received>
    <start_date>October 2014</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>June 8, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>IFNfreeCOG</acronym>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Neurocognitive Performance (computerized TAP - Test Battery for Attentional Performance)</outcome_measure>
      <outcome_measure>Change in Fatigue (Fatigue Impact Scale - FIS-D, questionnaire)</outcome_measure>
      <outcome_measure>Change in Health-Related Quality of Life (SF-36, questionnaire)</outcome_measure>
      <outcome_measure>Change in Emotional State (Hospital Anxiety and Depression Scale HADS, questionnaire)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02469012</url>
  </study>
  <study rank="85">
    <nct_id>NCT01979939</nct_id>
    <title>UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DCV/ASV/BMS-791325</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>416</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-102</other_id>
      <other_id>2013-002468-20</other_id>
    </other_ids>
    <first_received>November 4, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>October 9, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects in the naive cohort with sustained virologic response (SVR) 12</outcome_measure>
      <outcome_measure>Proportion of subjects in the experienced cohort with SVR12</outcome_measure>
      <outcome_measure>Proportion of subjects in each cohort who achieve HCV RNA &lt;LOQ TD/TND</outcome_measure>
      <outcome_measure>Proportion of subjects in each cohort who achieve HCV RNA &lt;LOQ TND</outcome_measure>
      <outcome_measure>Safety measured by frequency of serious AEs (SAEs) and discontinuations due to adverse events (AEs) through the end of treatment in each cohort</outcome_measure>
      <outcome_measure>Proportion of anemia defined as Hg &lt;10 g/dL on-treatment and Hg ≥10 g/dL at baseline , in each cohort</outcome_measure>
      <outcome_measure>Rates of selected grade 3-4 lab abnormalities (hematologic and liver function) in each cohort</outcome_measure>
      <outcome_measure>Proportion of subjects in each cohort achieving SVR12 associated with HCV geno subtype 1a vs 1b</outcome_measure>
      <outcome_measure>Proportion of subjects in each cohort achieving SVR12 associated with IL28B rs12979860 single nucleotide polymorphism (SNP) status (CC genotype or non-CC genotype)</outcome_measure>
      <outcome_measure>Proportion of subjects in each cohort achieving SVR12 associated with stage of liver fibrosis</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01979939</url>
  </study>
  <study rank="86">
    <nct_id>NCT02482077</nct_id>
    <title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF+RBV</intervention>
      <intervention type="Drug">SOF+DCV</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_HCV G2 Study</other_id>
    </other_ids>
    <first_received>June 23, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>June 23, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment</outcome_measure>
      <outcome_measure>HCV RNA levels and change during and after treatment.</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic breakthrough and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02482077</url>
  </study>
  <study rank="87">
    <nct_id>NCT02282709</nct_id>
    <title>Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">asunaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Foundation_LiverR</other_id>
    </other_ids>
    <first_received>October 23, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ImmunoDual</acronym>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV-specific T cell phenotype and function (a composite measure of (I) HCV-specific T-cell frequency and (II) phenotypic expression of memory markers and (III) inhibitory receptor markers</outcome_measure>
      <outcome_measure>NK cell phenotype and function (a composite measure of (I) NK cell frequency and (II) expression of activation and inhibitory markers (III) IFN-y production upon IL-12/IL-18 stimulation and (IV) Perforin granzyme production</outcome_measure>
      <outcome_measure>Gene expression levels of the type I IFN signaling pathway on whole blood samples measured by multiplex</outcome_measure>
      <outcome_measure>Gene expression levels of leukocyte populations before, during and after treatment measured by microarray</outcome_measure>
      <outcome_measure>Serum cytokines levels using multiplex platforms LUMINEX -100</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02282709</url>
  </study>
  <study rank="88">
    <nct_id>NCT02045693</nct_id>
    <title>Drug Interaction &amp; Methadone &amp; Buprenorphine</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methadone</intervention>
      <intervention type="Drug">DCV 3DAA FDC</intervention>
      <intervention type="Drug">BMS-791325</intervention>
      <intervention type="Drug">Buprenorphine</intervention>
      <intervention type="Drug">Naloxone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-108</other_id>
    </other_ids>
    <first_received>January 21, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>June 16, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum observed concentration (Cmax) of R-Methadone for Part 1</outcome_measure>
      <outcome_measure>Area under the concentration-time curve in one dosing interval (AUC(TAU)) of R-Methadone for Part 1</outcome_measure>
      <outcome_measure>Cmax of Buprenorphine and Norbuprenorphine for Part 2</outcome_measure>
      <outcome_measure>AUC(TAU) of Buprenorphine and Norbuprenorphine for Part 2</outcome_measure>
      <outcome_measure>Cmax of S-Methadone and Total Methadone for Part 1</outcome_measure>
      <outcome_measure>AUC(TAU) of S-Methadone and Total Methadone for Part 1</outcome_measure>
      <outcome_measure>Concentration at 24 hours (C24) of S-Methadone, Total Methadone and R-Methadone for Part 1</outcome_measure>
      <outcome_measure>Time of maximum observed concentration (Tmax) of S-Methadone, Total Methadone and R-Methadone for Part 1</outcome_measure>
      <outcome_measure>C24 of Buprenorphine and Norbuprenorphine for Part 2</outcome_measure>
      <outcome_measure>Tmax of Buprenorphine and Norbuprenorphine for Part 2</outcome_measure>
      <outcome_measure>Ratio of metabolite AUC(TAU) to parent AUC(TAU) (MR_AUC(TAU)) of Norbuprenorphine to Buprenorphine</outcome_measure>
      <outcome_measure>Cmax of of Daclatasvir (DCV) , Asunaprevir (ASV) , BMS-791325, and BMS-794712</outcome_measure>
      <outcome_measure>AUC(TAU) of DCV, ASV, BMS-791325, and BMS-794712</outcome_measure>
      <outcome_measure>Concentration at 12 hours (C12) of DCV, ASV, BMS-791325, and BMS-794712</outcome_measure>
      <outcome_measure>Tmax of DCV, ASV, BMS-791325, and BMS-794712</outcome_measure>
      <outcome_measure>MR_AUC(TAU) for BMS-794712 to BMS-791325</outcome_measure>
      <outcome_measure>Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), death and AEs leading to discontinuation</outcome_measure>
      <outcome_measure>Results of vital signs, Electrocardiograms (ECGs), Physical Examinations (PEs) and clinical labs</outcome_measure>
      <outcome_measure>Scores of Clinical Opiate Withdrawal Scale (COWS), Subjective Opiate Withdrawal Scale (SOWS), Objective Opiate Withdrawal Scale (OOWS), and Opiate Overdose Assessment (OOA)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Pennsylvania</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02045693</url>
  </study>
  <study rank="89">
    <nct_id>NCT02108639</nct_id>
    <title>To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DCV 3DAA FDC</intervention>
      <intervention type="Drug">BMS-791325</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-110</other_id>
    </other_ids>
    <first_received>April 7, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>July 9, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum observed plasma concentration (Cmax) for DCV, ASV, BMS-791325 and BMS-794712</outcome_measure>
      <outcome_measure>Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) for DCV, ASV, BMS-791325 and BMS-794712</outcome_measure>
      <outcome_measure>Concentration at 12 hours (C12) for (DCV, ASV, BMS-791325) and BMS-948158</outcome_measure>
      <outcome_measure>Time of maximum observed concentration (Tmax) for (DCV, ASV, BMS-791325) and BMS-948158</outcome_measure>
      <outcome_measure>Apparent total body clearance (CLT/F) for (DCV, ASV and BMS-791325 only)</outcome_measure>
      <outcome_measure>Trough observed plasma concentration (Ctrough) for (DCV, ASV, BMS-791325), BMS-794712 and BMS-948158</outcome_measure>
      <outcome_measure>Cmax fraction unbound (Cmaxfu) for (DCV, ASV, BMS-791325), BMS-794712 and BMS-948158</outcome_measure>
      <outcome_measure>AUC(TAU) fraction unbound (AUC(TAU) fu) for (DCV, ASV, BMS-791325), BMS-794712 and BMS-948158</outcome_measure>
      <outcome_measure>Protein Binding for DCV, ASV, BMS-791325 and BMS-794712</outcome_measure>
      <outcome_measure>Total amount recovered in urine (URt) for (DCV, ASV, BMS-791325) and BMS-794712</outcome_measure>
      <outcome_measure>Total percent of administered dose recovered in urine (%URt) for (DCV, ASV, and BMS-791325 only)</outcome_measure>
      <outcome_measure>Renal clearance (CLR) for DCV, ASV, BMS-791325, and BMS-794712</outcome_measure>
      <outcome_measure>Maximum observed concentration (Cmax) for BMS-948158</outcome_measure>
      <outcome_measure>Area under the concentration-time curve in 1 dosing interval (AUC (TAU)) for BMS-948158</outcome_measure>
      <outcome_measure>Safety based on occurrence of Adverse Event (AEs), Serious adverse event (SAEs) and AEs leading to discontinuation</outcome_measure>
      <outcome_measure>Safety based on abnormalities in vital sign measurements</outcome_measure>
      <outcome_measure>Safety based on findings on ECG measurements and physical examinations</outcome_measure>
      <outcome_measure>Safety based on Marked abnormalities in clinical laboratory test findings</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
      <state>Minnesota</state>
      <state>Tennessee</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02108639</url>
  </study>
  <study rank="90">
    <nct_id>NCT02057003</nct_id>
    <title>Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAA against HCV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
      <collaborator>Hospital Universitario Reina Sofia</collaborator>
      <collaborator>Hospital Universitario Virgen de la Victoria</collaborator>
      <collaborator>Hospital Universitario de la Princesa</collaborator>
      <collaborator>Hospitales Universitarios Virgen del Rocío</collaborator>
      <collaborator>Hospital Universitario Carlos Haya</collaborator>
      <collaborator>Hospital Torrecárdenas</collaborator>
      <collaborator>Complejo Hospitalario Universitario de Huelva</collaborator>
      <collaborator>Hospital Puerta del Mar</collaborator>
      <collaborator>Hospital Universitario Virgen Macarena</collaborator>
      <collaborator>Hospital de La Línea</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPAVIR-DAA</other_id>
    </other_ids>
    <first_received>January 6, 2014</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients who achieve SVR to DAA-based therapy as measure of efficacy</outcome_measure>
      <outcome_measure>Number of patients who develop severe adverse events as measure of safety</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to a BOC-based regimen as compared to numbers of patients who achieve SVR to a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who reach undetectable HCV-RNA at week 4 of PI-based therapy as a measure of on-treatment response to therapy.</outcome_measure>
      <outcome_measure>Number of patients who develop adverse events during a BOC-based regimen as compared to numbers of patients who develop adverse events during a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to an interferon-free regimen.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02057003</url>
  </study>
  <study rank="91">
    <nct_id>NCT02333292</nct_id>
    <title>Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">SMV</intervention>
      <intervention type="Drug">DCV</intervention>
      <intervention type="Drug">LED</intervention>
      <intervention type="Drug">PTV/OTV</intervention>
      <intervention type="Drug">DBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GEHEP-MONO</other_id>
    </other_ids>
    <first_received>December 15, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>FPSMON201401</acronym>
    <primary_completion_date>November 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Patients with Sustained Virological Response</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events</outcome_measure>
      <outcome_measure>Identification of predictors of SVR</outcome_measure>
      <outcome_measure>Analyze efficacy and safety in patients that receive methadone maintenance therapy</outcome_measure>
      <outcome_measure>Analyze efficacy and safety according to previous treatment outcome</outcome_measure>
      <outcome_measure>Analyze efficacy and safety in patients with cirrhosis</outcome_measure>
      <outcome_measure>Evaluate impact of SVR on biological, elastographical and clinical parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02333292</url>
  </study>
  <study rank="92">
    <nct_id>NCT02628717</nct_id>
    <title>Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Medical University of Vienna</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>I3MHCV</other_id>
    </other_ids>
    <first_received>December 3, 2015</first_received>
    <start_date>July 2013</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>December 10, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>AURIC</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients with sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>On treatment predictability of SVR</outcome_measure>
      <outcome_measure>Number of patients with liver events (Mortality, Hepatic decompensation, Variceal Bleeding,Hepatocellular Carcinoma, Need for Liver Transplantation) on longterm clinical outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02628717</url>
  </study>
  <study rank="93">
    <nct_id>NCT01888900</nct_id>
    <title>New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cirrhosis</condition>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir and Daclatsvir</intervention>
      <intervention type="Drug">Asunaprevir, daclatsvir, peginterferon, ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>130150</other_id>
      <other_id>13-DK-0150</other_id>
    </other_ids>
    <first_received>June 26, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>November 6, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Changes in interferon stimulated genes during therapy with asunaprevir and dacalatsvir</outcome_measure>
      <outcome_measure>Safety and efficacy of asunaprevir and dacalatsvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01888900</url>
  </study>
  <study rank="94">
    <nct_id>NCT02613403</nct_id>
    <title>Efficacy and Safety of MK-3682B (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C</condition>
      <condition>Digestive System Diseases</condition>
      <condition>Flaviviridae Infections</condition>
      <condition>Hepatitis, Viral, Human</condition>
      <condition>Liver Diseases</condition>
      <condition>RNA Virus Infections</condition>
      <condition>Virus Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MK- 3682B</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3682-021</other_id>
      <other_id>2015-001483-19</other_id>
    </other_ids>
    <first_received>November 20, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>November 20, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12)</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one adverse event</outcome_measure>
      <outcome_measure>Number of participants who discontinued study drug due to an adverse event</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one serious adverse event</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one drug-related adverse event</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one serious and drug-related adverse event</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one laboratory adverse event of interest</outcome_measure>
      <outcome_measure>Number of participants who experienced AST/ALT &gt;5 x upper limit normal at Week 4 or later</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02613403</url>
  </study>
</search_results>
